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Abstract 
 
An essential event during early pregnancy is the invasion of trophoblasts into the 
maternal decidua, which is necessary for proper implantation and establishment of 
maternal-fetal interface and ultimately allows for proper nutrient exchange and 
immunological tolerance of the growing fetus. For this invasion to occur, cells originating 
from the trophectoderm undergo an epithelial to mesenchymal transition to become 
invasive extravillous trophoblasts and begin invading the uterine decidual tissue. Through 
the secretion of matrix metalloproteinases and through interactions with many cytokines 
and cell-adhesion molecules, this well-orchestrated process of trophoblast invasion 
results in extensive remodeling of the maternal spiral vasculature by the extravillous 
trophoblasts. Ultimately, the spiral arteries are transformed from high resistance, low flow 
vessels to low resistance, high flow vessels to allow for adequate perfusion of the placenta 
and developing fetus.    
Preeclampsia is a leading cause of maternal morbidity worldwide and is associated 
with the onset of hypertension and proteinuria, typically after 20 weeks of gestation. While 
the hypertension typically resolves following delivery of the fetus and placenta, both the 
mother and growing child are faced with long-term adverse health effects such as the 
development of cardiovascular disease and metabolic disorders. Preeclampsia is 
characterized by widespread maternal inflammation and endothelial dysfunction triggered 
by the secretion of soluble factors from the placenta into the maternal circulation. It is 
thought that the onset of these adverse systemic conditions is initiated by poor placental 
 xii 
perfusion and pathologically hypoxic conditions in the placenta. In many cases of 
preeclampsia, there is evidence of shallow trophoblast invasion which results in 
incomplete spiral artery transformation, ultimately leading to poor placental perfusion. 
However, the exact mechanisms underlying the inadequate extravillous trophoblast 
invasion and remodeling are incompletely understood. 
LIN28 is an RNA binding protein that is highly expressed in embryonic stem cells, 
fetal tissues and many cancers, and was discovered as a regulator of the maturation of 
the Let-7 family of miRNAs. However, as an RNA binding protein, LIN28 has been shown 
to interact with thousands of mRNA transcripts, leading to both increased and decreased 
protein expression, and control of many cellular processes such as differentiation, 
proliferation, migration, invasion, and cellular metabolism. In vertebrates, LIN28 exists as 
two highly homologous paralogs, LIN28A and LIN28B, however LIN28B is slightly larger 
and contains a nuclear localization signal not found in LIN28A. While they both function 
to inhibit Let-7 maturation, there is evidence to suggest they also have independent 
functions.  
 Given the primary role of LIN28A and LIN28B in modulating cell metabolism, 
differentiation and invasion, we hypothesized that LIN28A and/or LIN28B regulates 
trophoblast differentiation and invasion, and that its dysregulation may contribute to 
preeclampsia. We found that LIN28B mRNA expression is ~1300-fold higher than LIN28A 
in human term placenta and is the predominant paralog expressed in human primary 
cytotrophoblasts, syncytiotrophoblasts, and decidual cells. We also found that LIN28B 
mRNA and protein levels are significantly reduced in human placentas from preeclamptic 
pregnancies compared to placentas from normal pregnancies, while LIN28A expression 
 xiii 
is unchanged. Upon investigation of human first trimester placenta sections, we found 
that LIN28B is more highly expressed in the invasive extravillous trophoblasts and 
syncytial sprouts compared to villous trophoblasts. To support this with in vitro evidence, 
we found that overexpression of LIN28B in human HTR8/SVneo cells resulted in 
increased proliferation, migration and invasion, while knockdown of LIN28B in JEG3 cells 
resulted in decreased proliferation. Furthermore, knockdown of LIN28B in JEG3 cells led 
to decreased expression of SYN-1, ELABELA, and the chromosome 19 miRNA cluster, 
with accompanying increases in the pro-inflammatory cytokine TNFα and ITGβ4, an 
integrin enriched on non-invasive trophoblasts. Moreover, culture of JEG3 and BEWO 
cells in hypoxia resulted in significantly decreased levels of LIN28B mRNA and protein 
expression, as well as syncytin-1 and ELABELA mRNA levels, while TNFα was 
increased. These results provide the first evidence that LIN28B is the predominant 
paralog expressed in human placenta and decreased LIN28B may play a crucial role in 
PE pathogenesis by reducing trophoblast invasion, syncytialization and by promoting 
inflammation. 
 
1 
 
 
 
 
 
 
Chapter 1 
 
Trophoblast Differentiation and Preeclampsia 
 
Preeclampsia (PE) 
Preeclampsia is a severe disease of pregnancy with clinical manifestations that 
include systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg, 
accompanied by proteinuria >300mg/day, and is typically diagnosed after 20 weeks of 
gestation (1). Pathological manifestations of this disease include systemic maternal 
endothelial dysfunction which results in widespread vasoconstriction as well as elevated 
vascular permeability (2). Worldwide, PE represents the second most common cause of 
maternal morbidity, affecting between 3% and 10% of all pregnancies, with mounting 
evidence indicating a significant increase in the incidence of PE over the last 20 years (3-
5). Furthermore, up to 25% of cases of intrauterine growth restriction (IUGR) and up to 
20% of preterm births are attributed to PE (6). Although the exact etiology of PE is poorly 
understood, it is speculated to arise due to either 1) normal placental-derived factors 
interacting with maternal conditions that are predisposed or susceptible to cardiovascular 
disease (maternally driven PE) (7); or 2) the exposure of the placenta to progressive, 
long-term hypoperfusion and hypoxic conditions, resulting in the release of anti-
angiogenic and pro-inflammatory soluble placental factors (placentally driven PE) (8). 
Although clinical manifestations of PE do not typically arise until after 20 weeks of 
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gestation, it is thought that PE begins developing early in the pregnancy, well before any 
clinical adverse effects are detected. 
 
Risk factors associated with preeclampsia 
There are many risk factors and predispositions associated with the development 
of PE. It has been shown that advanced maternal age (i.e. maternal age >35) is a risk 
factor for PE, although it has also been shown that the incidence of PE is increasing faster 
amongst women of younger age when compared to older age (9, 10). Furthermore, 
nulliparous pregnancies are more strongly associated with PE when compared to 
multiparous pregnancies, possibly due to higher levels of circulating soluble fms-like 
tyrosine kinase-1 (sFLT-1) in the maternal serum (11). In addition to increased maternal 
age and nulliparous pregnancies, elevated BMI, African-American race, and the presence 
of gestational diabetes are frequently associated with the onset of PE (12-15). Lastly, 
maternal infections and the resulting inflammation is associated with an increased risk for 
the development of PE. For instance, urinary tract infections and periodontal disease, 
which can be caused by many different bacterial microorganisms, are strongly associated 
with the onset of PE (16, 17). In addition, numerous maternal viral infections, such as 
CMV, HIV, and HSV-2, have been linked to the onset of PE (18, 19). It is thought that 
high levels of proinflammatory cytokines as a result of these different infections plays a 
part in increased oxidative stress and increased circulating anti-angiogenic proteins, thus 
contributing to the maternal endothelial dysfunction associated with PE (18). It is 
important to keep these predispositions in mind when studying the underlying 
development and etiology of PE. 
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Long- and short-term adverse health effects associated with preeclampsia 
To date, the only curative treatment for PE is termination of the pregnancy and/or 
delivery of the fetus and placenta. Although the widespread maternal endothelial 
dysfunction and hypertension typically resolve within approximately one month following 
delivery, short-term and long-term adverse health outcomes exist, for both the mother 
and child (20). For instance, fetuses exposed to PE in utero are often born early and/or 
small for gestational age. Furthermore, long-term population-based follow-up studies 
indicate that children exposed to PE are at a significantly higher risk for the development 
of long-term cardiovascular, endocrine, and metabolic diseases, such as diabetes and 
hypertension (21-23). On the other hand, short-term adverse health effects on the mother 
include antenatal stroke, deteriorated kidney function, elevated liver enzymes, severe 
headaches and visual disturbances, and elevated circulating C-reactive protein, which 
indicates the presence of systemic inflammation (24-26). In addition, woman who develop 
PE are four-fold more likely to develop cardiovascular disease throughout their lifetime 
when compared to woman with similar pregnancy numbers and no history of PE (27). 
Given these long-term adverse outcomes associated with a disease of this prevalence, it 
is imperative that the etiology of the disease is further understood, and better treatment 
options are developed.  
 
Decidualization 
 Decidualization, beginning after ovulation triggered by high levels of progesterone, 
is the process in which the decidua is formed and involves extensive morphological and 
biochemical changes within the endometrium in preparation of implantation of the 
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developing blastocyst (28). Prior to formation of the decidua, endometrial stromal cells 
(EnSCs) appear fibroblast like, with little cytoplasm and elongated nuclei. During 
decidualization, EnSCs adopt a more round nuclei structure and begin to swell due to 
accumulation of lipid droplets and glycogen in the cytoplasm (29). In addition to 
morphological changes within the EnSCs, the extracellular matrix is extensively 
remodeled to facilitate implantation and invasion by trophoblasts. The extracellular 
composition of collagen IV and laminin is greatly increased during decidualization, and 
eventually this basement membrane surrounds EnSCs, which facilitates interactions 
between the decidua and trophoblasts (30). To complement the increase in dense 
extracellular matrix and basement membrane, EnSCs in the decidua begin secretion of 
prolactin and IGFBP-1, which are important for modulation of immune cell infiltration and 
trophoblast invasion (31, 32). In addition to the extracellular matrix composition changes, 
the mature decidua is characterized by the presence of a large population of decidual 
natural killer (dNKs) cells around the spiral arteries and endometrial glands (28). Unlike 
peripheral blood natural killer cells, these dNKs are not cytotoxic and do not typically kill 
trophoblasts (33). Rather, the dNKs function to secrete cytokines and other factors, such 
as MMPs, that assist in the disruption of the vascular extracellular matrix and vascular 
cell-cell interactions that assists in vascular trophoblast invasion, a process that will be 
discussed in more detail later. It is important to note that decidual cells (DCs) express 
vimentin, but not cytokeratin, as opposed to invasive trophoblasts which express 
cytokeratin, but not vimentin, thus making the two cell types easily distinguishable using 
immunohistochemical staining (34-36).  
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Development of the trophectoderm and inner cell mass 
 The embryo begins as a totipotent, single celled organism following fusion of an 
oocyte and sperm. After successful fusion, the first differentiation event of embryogenesis 
and multiple cycles of cell division occur, which ultimately results in two distinct 
populations which arise due to asymmetrical division during the transition from the 8- to 
16-cell stage. Blastomeres on the outer surface of the embryo display distinct polarity and 
gene expression, while blastomeres on the inner portion of the embryo lack polarity and 
display an entirely separate distinct set of genes (37, 38). The polarized blastomeres on 
the outer surface of the embryo are destined to differentiate into the trophectoderm (TE), 
while the blastomeres on the inner portion of the embryo become the pluripotent inner 
cell mass (ICM), and eventually, the three germ layers (Figure 1). The differential gene 
expression between these two layers is achieved through many different mechanisms, 
such as histone modification, DNA methylation, and differential miRNA expression (39-
41). Currently, the exact time in which developmental bias towards the TE or the ICM 
remains controversial, with some reports indicating this begins as early as the 2-cell 
stage, and others indicting this begins around the 8-cell stage (38). Due to ethical 
concerns, the study of human ICM and TE formation and function has proven difficult. 
Yet, despite some species-to-species variation, a wealth of knowledge has been accrued 
based on studies of mouse tissues.  
 The ICM is a pluripotent cluster of cells within the primordial embryo which will 
eventually differentiate into the three germ layers and, ultimately, the developing fetus. 
One of the first factors identified in formation and maintenance of the ICM was the 
transcription factor Oct4. Oct4 is a transcription factor that is expressed substantially 
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higher in the ICM compared to the TE, and regulates the expression of FGF-4. Oct4 
induced expression of FGF-4 is highly important, as FGF-4 is secreted from the ICM in a 
paracrine manner and stimulates growth and proliferation of the developing TE (42). 
Furthermore, knockout of Oct4 is embryonically lethal and results in an ICM that is not 
pluripotent and constrained to differentiation along the trophoblast lineage (42). Nanog is 
another transcription factor that regulates formation of the ICM. In a manner similar to 
Oct4, Nanog’s expression is restricted to the ICM, and Nanog-null embryos fail to develop 
an epiblast, suggesting a lack of pluripotency of the ICM (43). Furthermore, culturing of 
Nanog-deficient embryonic stem cells (ESCs) results in spontaneous differentiation into 
the extraembryonic lineage, further indicating that Nanog is essential for maintenance of 
pluripotency of the ICM (43). Another transcription factor, SOX2, is also required for 
proper development and pluripotency of the ICM. Much like Oct4, isolated cells from 
Sox2-null ICM spontaneously differentiate along the trophoblast lineage, suggesting it is 
also vital for the ICM (44). Sox2 forms a heterodimer with Oct4, and together they regulate 
the expression of many genes that protect the pluripotency of the ESCs, while disruption 
of this interaction leads to differentiation into the primitive endoderm (45, 46). The careful 
balance of these important transcription factors, among others, within the ICM not only 
maintains pluripotency, but also directs cell differentiation along specific lineages to allow 
for proper development of the three germ layers and the fetus (47, 48).  
Polar epithelial cells of the TE differentiate into trophoblasts, which form the 
building blocks of the placenta, and are indispensable for initial implantation of the 
blastocyst in the uterine wall.  Development of the TE, and later differentiation, requires 
a set of genes which are distinct from that of the ICM (38, 48). For instance, the 
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transcription factor Tead4 is highly expressed in the TE, and Tead4 knockouts display 
lethality prior to implantation (49, 50). Tead4 is responsible for the activation of many 
downstream genes that are required for proper development of the TE, such as the FGF 
receptor and the transcription factor Cdx2. Like Tead4, Cdx2 is highly expressed in the 
TE, and is required for its development, as Cdx2-null blastocysts fail to develop a proper 
TE and fail to implant (51). Furthermore, Cdx2-null blastocysts do not develop trophoblast 
stem cells, whereas forced expression of Cdx2 in ESCs results in conversion to 
trophoblast stem cells (52). Through the activation of other genes and transcription 
factors, Cdx2 promotes symmetrical cell division during early blastocyst formation and 
promotes cell polarity, which is crucial for proper TE development. Interestingly, Cdx2 has 
also been shown to occupy the promoter region of Oct4 in order to prevent its expression 
within the TE layer (38). Tight regulation of these genes, among many others, is required 
for the proper development of the TE and, ultimately, implantation into the uterine wall 
and development of the functional placenta.  
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Figure 1. Simplified schematic representation of blastocyst prior to implantation.  
 
Polar epithelial cells of the trophectoderm, which differentiate into trophoblasts and 
extraembryonal tissues such as the placenta, attach to and invade the maternal 
endometrium. Conversely, non-polar pluripotent cells of the inner cell mass eventually 
differentiate into the three germ layers, and ultimately the fetus. 
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The placenta  
 The placenta is a vital organ of pregnancy that serves as a bridge between the 
developing fetus and the maternal uterus. As a key regulator of nutrient uptake, gas 
exchange, waste elimination, and hormone production, an appropriately developed and 
functioning placenta is vital for the healthy development and progression of the fetus and 
pregnancy. In humans, the placenta develops circumferentially with the most extensive 
invasion at the center and less extensive invasion towards the periphery, which results in 
a discoid shape upon complete development (53, 54). This invasion, in addition to many 
other molecular, biochemical, and physiological changes that occur are required to 
produce favorable conditions for the developing fetus.  
 
Placentation in early pregnancy 
 Human decidualization begins on day 14 of the menstrual cycle, in preparation for 
adhesion of the blastocyst to the uterine decidua. Blastocyst adhesion, which takes place 
approximately one week after fertilization, is the first step in implantation, and triggers the 
development of the maternal-fetal junctional zone (55). Implantation and formation of the 
maternal-fetal junctional zone triggers trophoblast proliferation and differentiation into 
syncytiotrophoblasts (STs), as well as penetration of the uterine epithelium and which 
triggers erosion of maternal capillaries and glands, allowing blood and gland contents to 
enter the lacunae (56). This process also initiates trophoblast differentiation into villous 
cytotrophoblasts (CTs), which proliferate to form primary, secondary, and tertiary villi, or 
extravillous trophoblasts (EVTs), which further differentiate into interstitial EVTs or 
endovascular EVTs. EVTs have the capacity to degrade extracellular matrix, allowing 
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them to invade the maternal decidua and remodel the maternal spiral arteries (57, 58). 
Furthermore, non-invasive CTs on the anchoring villi appear to express integrinβ4, 
whereas invasive EVTs express integrinβ1, indicating that the differentiation from non-
invasive to invasive trophoblasts involves changes in cell-surface integrins (59-61). 
The uterine vasculature undergoes extensive structural and physical changes 
during gestation to provide adequate blood flow and nutritional support to the uterus, 
placenta, and growing fetus. These changes, along with formation of the placenta and 
implantation process (i.e. placentation) during early pregnancy, are a very complex and 
intricately orchestrated chain-of-events that ultimately results in the development of 
adequate utero-placental perfusion. While all of the details underlying this process are 
not completely understood, it is well established that early in the pregnancy, 
approximately 5-8 weeks after implantation, fetally derived trophoblasts undergo an 
epithelial-to-mesenchymal transition (EMT) to become EVTs and begin invading the 
maternal tissue, a process which is typically completed by 20 weeks of gestation (62, 63). 
The invasion of EVTs into maternal tissues is categorized as vascular invasion (invasion 
of the EVTs resulting in remodeling of the maternal spiral arteries) and interstitial invasion 
(invasion of the EVTs to the space between arteries). Together, this invasion of the 
maternal tissue paves the way to adequate placental perfusion. 
 
Interstitial EVT invasion 
Interstitial trophoblast invasion involves invasion of EVTs from anchoring villi into 
the decidual tissue located between maternal spiral arteries. Through the release of 
MMPs, such as MMP-2, -9, and -12, it is thought that these interstitial trophoblasts begin 
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degrading extracellular matrix and promote further invasion. In addition to the release of 
MMPs, activation and recruitment of growth factors, cell-surface receptors, and cytokines 
such as IL-8 and IL-13, by EVTs further stimulates the process of proper implantation and 
development (64-66). In fact, it has recently been shown that MMP-12 has elastolytic 
capacities, which assists in EVT remodeling of the spiral arteries (67). Under normal 
circumstances, the interstitial invasion of the EVTs eventually reaches the myometrial 
area and terminates with the fusion of EVTs to form multinucleated giant cells (68). In 
parallel to the interstitial trophoblast invasion and degradation of the decidual extracellular 
matrix, invasive EVTs also invade and remodel the maternal spiral arteries. 
 
Vascular EVT invasion 
The spiral artery vascular invasion by EVTs is a process in which high-resistance, 
small diameter spiral arteries are remodeled and transformed into low-resistance, large 
diameter vessels with increased flow (69). This intricate process is initiated by the 
invasion of EVTs into the distal portions of the uterine arteriole, followed by retrograde 
invasion and migration until reaching the spiral artery (70). Upon reaching the lumen of 
the spiral artery, these endovascular trophoblasts accumulate, resulting in the formation 
of the trophoblast plug (71). These trophoblast plugs within the maternal spiral arteries 
prevent blood flow from reaching the developing placenta and fetus during the early 
weeks of pregnancy. However, to allow for proper nutrient delivery, invasive extravillous 
trophoblasts also invade the uterine glands, eventually eroding the epithelium and 
allowing their contents to be secreted into the intervillous space, thus providing adequate 
nutrient flow prior to complete spiral artery remodeling throughout the first ~10-12 weeks 
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of gestation (72, 73). By the 12th week of gestation, the trophoblast plugs within the spiral 
arteries loosen and degrade, which allows for the flow of maternal blood into the 
intervillous space of the developing placenta (74). However, the remodeling of the 
maternal spiral arteries does not stop with the degradation of the trophoblast plugs. The 
EVTs continue to migrate and invade in a retrograde fashion until the myometrial portion 
of the spiral artery. During this invasion, there is a downregulation of surface adhesion 
receptors, such as E-cadherin, on the EVTs, while there is an upregulation of VE-
cadherin, VECAM-1, and PECAM-1, which facilitates invasion and migration of the 
endothelial cell layer of the spiral arteries (55, 75, 76). Along with EVT invasion of the 
spiral arteries comes vascular endothelial cell apoptosis, followed by the accumulation of 
trophoblasts, thus forming a new trophoblast cell endothelial-like barrier lining the lumen 
of the spiral artery (77). It is thought that the apoptotic endothelial cells are rapidly 
removed by phagocytosis to prevent the secretion of immunogenic contents from within 
the dying cell (70).  
In addition to the removal and replacement of endothelial cells by trophoblasts 
during spiral artery remodeling, vascular smooth muscle cells (VSMCs) are also altered. 
Under typical conditions, VSMCs exist in the functional, contractile phenotype. However, 
it is well known that they can switch from this contractile phenotype to the synthetic, 
proliferative phenotype (78, 79). During spiral artery remodeling, loss of the VSMC 
contractile phenotype is thought to be associated with the loss of the layered structural 
organization of the medial layer of the spiral artery. In addition to this loss of VSMC 
organization, trophoblast invasion also results in VSMC apoptosis and replacement of the 
VSMCs with fibrinoid deposits and trophoblasts (80). It is important to note that, while the 
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vast majority of vascular remodeling takes place in the decidual spiral arteries, the 
decidual veins and lymphatics are also remodeled, albeit to a much lesser extent. It is 
thought that this remodeling serves to increase the maternal-fetal interface, thus allowing 
increased nutrient exchange (81). Overall, the complex remodeling of the decidual 
vasculature results in a substantial increase in the diameter of the lumen and diminished 
contractile capabilities of the arteries, thus allowing adequate maternal blood flow into the 
intervillous space to support the growing placenta and embryo. However, in PE affected 
placentas, this remodeling is often impaired, resulting in inadequate blood flow and 
prolonged, progressive hypoperfusion and hypoxic conditions for the developing fetus.  
 
Syncytialization  
 Trophoblast syncytialization is the process in which CTs fuse to form a continuous 
layer of multinucleated cells, referred to as the syncytium. Primary trophoblast 
syncytialization occurs at the time of implantation when the blastocyst first comes into 
contact with maternal decidua and serves as the basis for the development of the 
syncytium. This initial lateral fusion of neighboring trophoblasts allows for proper 
attachment and implantation, resulting in degradation of the maternal capillaries and 
glands which allows blood to enter the newly formed lacunae (56). To aid in growth of the 
evolving syncytial layer, CTs distal to the STs continue to proliferate and fuse with the 
STs, which leads to the formation of projections that result in areas of empty space and 
trabeculae, which eventually become the placental villi. This initial attachment and 
primary syncytialization culminates around post fertilization day 11 when the blastocyst is 
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fully implanted (82). On the other hand, secondary syncytialization occurs continuously 
throughout the duration of the pregnancy to maintain placental epithelial barrier integrity.   
Secondary syncytialization results in formation of the mature syncytium which 
exists as a functional border between the maternal circulation and the developing fetus. 
The syncytium is the principal site of maternal-fetal gas and nutrient exchange, as well as 
waste elimination. Health and function of the syncytium is maintained by continual cellular 
replenishment by fusion of villous CTs into the ST layer, which involves the transfer of the 
nucleus and cytoplasm of the CTs into the syncytium (83). The intricate balance of the 
syncytium is maintained by continual shedding of syncytial cells and apoptotic material 
into the maternal circulation to allow for the constant addition of newly fused CTs (82, 84, 
85). Proper formation and maintenance of the syncytium is vital, and dysregulation can 
result in pregnancy failure or abnormal outcomes such as PE or IUGR (86, 87). 
Fusion of CTs to the syncytial layer of the placental villi requires a complex 
cascade of events that includes membrane destabilization, expression of cell fusogens, 
and ultimately the uptake of cellular contents of the fusing CT into the syncytium. While 
the exact signaling mechanisms responsible for proper fusion remain an area of active 
investigation, it is well established that SYN-1 plays a vital role in this process. SYN-1 is 
an envelope protein belonging to the human endogenous retrovirus family W, which is 
highly expressed in STs of the placenta and helps mediate the fusion of CTs into the 
syncytium (88). Many signaling cascades have been implicated in the expression of SYN-
1, with most working through the activation of GCM-1, a transcription factor responsible 
for the expression of SYN-1, and to a lesser extent the related protein SYN-2 (89-91). For 
instance, cAMP/PKA dependent post-translational modifications of GCM-1 results in 
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stabilization of the protein and enhanced expression of SYN-1 (90). Furthermore, in vitro 
inhibition of ERK1/2 or p38MAPK results in reduced syncytialization, while activation of 
p38MAPK has been shown to induce SYN-1 expression through activation of GCM-1 (92, 
93). Lastly, it has recently been shown that activation of the β-catenin pathway results in 
the upregulation of GCM-1, which in turn leads to the induced expression of SYN-1 and 
syncytialization (94). Overall, the development and maintenance of a functional syncytium 
is necessary for the healthy progression of the pregnancy and impaired syncytium 
formation may result in pregnancy related disorders such as PE. 
 
Impaired vascular remodeling in preeclampsia 
 Shallow invasion and impaired vascular remodeling of the maternal spiral arteries 
(i.e. impaired placentation) has been well established as an underlying pathology of PE 
(95, 96). In contrast to the extensive remodeling that is observed in normal pregnancies, 
spiral artery transformation appears to be incomplete in PE, with fewer endovascular 
trophoblasts and more abundant spiral arteries that retain an intact endothelial and VSMC 
layer (Figure 2) (97). Furthermore, it has been shown that invasive EVTs from PE 
affected placentas display reduced VE-cadherin and integrin α1, which potentially 
contributes to the reduced endovascular invasion evident in the disease (98). Due to the 
inadequate remodeling, the spiral arteries fail to sufficiently dilate, thus resulting in 
inadequate delivery of maternal blood to the placenta and exposure of the placenta to 
increasingly hypo-perfused and hypoxic conditions. As a result of these hypoxic 
conditions, there is a marked downregulation of syncytialization mediator SYN-1, leading 
to reduced syncytiotrophoblast formation, which is evident in placentas complicated by 
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PE (99-101). It is important to note that, while abundantly evident in PE, shallow 
implantation is implicated in other pathological conditions of pregnancy, such as IUGR 
and some cases of pre-term birth (102, 103). In addition to the physical changes in the 
placenta induced by the aberrant invasion and remodeling of the spiral arteries, the long-
term hypo-perfusion and hypoxia has been shown to induce secretion of soluble factors 
into the maternal circulation that promote inflammation and widespread endothelial cell 
dysfunction (104, 105). Currently, the underlying molecular and biochemical aberrations 
that cause impaired invasion and vascular remodeling in PE is currently unknown. 
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Figure 2. Simplified schematic showing spiral artery remodeling by invasive EVTs. 
 
In diseases such as PE, impaired spiral artery remodeling by invasive EVTs results in 
maintained spiral artery vascular tone and decreased maternal blood flow to the 
developing fetus and placenta (left). In contrast, adequate vascular remodeling (right) by 
invasive EVTs results in increased lumen diameter and loss of contractile phenotype 
allowing for sufficient maternal blood flow to the placenta and developing fetus.  
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sFLT-1 and preeclampsia 
 Vascular endothelial growth factor (VEGF) is known to be a promoter of 
angiogenesis and plays a role in regulating blood pressure and proteinuria. Circulating 
VEGF can induce endothelial dependent vasodilation through the AKT dependent 
phosphorylation and activation of endothelial nitric oxide synthase (eNOS), as well as 
induction of prostacyclins, thus decreasing blood pressure (106). Conversely, VEGF 
signaling inhibitors have been shown to induce hypertension though disruption of 
endothelial dependent vasodilation, and proteinuria, through disruption of the glomerular 
barrier integrity (107, 108). sFLT-1 is a soluble splice variant of the VEGF receptor FLT-
1, which lacks the transmembrane and cytoplasmic domain of the receptor. Circulating 
sFLT-1 can bind and sequester circulating VEGF and placental growth factor (PlGF), thus 
acting as an inhibitor of VEGF signaling and promoting hypertension and proteinuria 
(109). sFLT-1 is expressed by many tissue types, including the placenta, and has been 
shown to be upregulated in the placenta, the amniotic fluid, and in the maternal circulation 
of pregnancies complicated by PE, with the circulating levels of sFLT-1 typically 
normalizing within ~48 hours of delivery (104, 110-112). Additionally, hypoxia has been 
shown to upregulate sFLT-1 in CTs (113). Furthermore, exogenous overexpression of 
sFLT-1 in pregnant or non-pregnant rodents results in severe hypertension as well as 
renal lesions, further implying that sFLT-1, not necessarily the placenta, is responsible for 
the maternal endothelial dysfunction (104). In the time since these findings, sFLT-1 has 
been investigated as a biomarker for the prediction of PE early in pregnancy, however 
sFLT-1 alone is not enough to accurately predict the development of the disease. Rather, 
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the sFLT-1/PlGF ratio has shown promise in clinical studies as a predictive biomarker for 
early onset PE, although more trials are currently underway (114-116). 
 
Soluble endoglin in preeclampsia 
 The exogenous delivery of sFLT-1 does not induce hemolysis and 
thrombocytopenia, which are symptoms of HELLP syndrome associated with severe PE, 
which indicates that other soluble, placental derived factors may be involved in the 
disease development. For instance, Endoglin (Eng), a cell-surface receptor for 
transforming growth factor β1 (TGFβ1) and β3 (TGFβ3), is highly expressed on 
endothelial cells and STs, and has been shown to associate with eNOS to regulate 
vascular tone (117-119). Gene expression profiling of placental tissues obtained from 
normal and PE pregnancies indicate that Eng is upregulated in PE. Furthermore, a 
soluble form of Endoglin (sEng), is shown to be upregulated in the serum of women with 
PE, and its expression level correlates with disease severity (105). In addition to being 
elevated in the serum of PE affected women, exogenous overexpression of sEng in 
rodents resulted in hypertension, which was exacerbated by co-overexpression of sFLT-
1 and sEng. Moreover, co-overexpression of sFLT-1 and sEng resulted in severe 
proteinuria and biochemical evidence of HELLP syndrome (105). Because the increase 
in sEng can be observed in the serum of women as many as 10 weeks before the onset 
of PE, it has been posited as a predictive biomarker for the development of the disease. 
Together with sFLT-1, sEng plays a major role in contributing to the systemic adverse 
effects observed in PE.   
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C19MC in the placenta and preeclampsia  
 The chromosome 19 microRNA (miRNA) cluster (C19MC) is one of the largest 
known miRNA clusters, is primate specific, genomically imprinted, and expressed almost 
exclusively in the placenta (120). The C19MC spans over 100kb of genomic DNA, with 
its expression resulting in over 40 different mature miRNAs (121). It has been shown that 
these miRNAs are highly expressed in CTs and STs and can be shed into the maternal 
circulation through exosome shedding from the STs (122). In fact, the miRNAs from the 
C19MC cluster are among the most abundantly detected miRNAs in the placenta and in 
the serum of pregnant women. Although the complete role of these miRNAs in the 
placenta is not currently known, it has been shown that the C19MC miRNAs can confer 
viral resistance to trophoblasts, and that some miRNAs of the cluster modulate the 
migration, but not proliferation, of trophoblasts (123-125). However, while the role of the 
C19MC in the placenta is incompletely understood, it should be noted that the expression 
of some miRNAs of the C19MC have been shown to be downregulated in the placenta of 
PE affected pregnancies, while upregulated in the serum of PE affected women (126, 
127). 
 
Inflammation in preeclampsia 
 Maternal immune tolerance is a key facet of pregnancy. Proper interaction 
between the maternal immune system and the placenta and developing fetus is required 
for placentation and success of the pregnancy. However, PE is often associated with 
aberrant activation of the immune system characterized by increased circulating levels of 
proinflammatory cytokines. For instance, the proinflammatory cytokine TNFα is highly 
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expressed early in pregnancy and is necessary for proper implantation, while 
overproduction of this cytokine has been linked with implantation failure and recurrent 
pregnancy loss (128). Moreover, TNFα has been reported to be upregulated in the 
placenta, the amniotic fluid, and the maternal circulation in pregnancies affected by PE 
(129-131). The increased level of circulating TNFα can contribute to endothelial 
dysfunction by increasing endothelial cell permeability and increasing the expression of 
adhesion molecules on the endothelial layer. Aberrant TNFα signaling has been shown 
to lead to a reduction in NO signaling by reducing the half-life of NOS mRNA, while also 
increasing the expression of preproendothelin-1, the precursor to the potent 
vasoconstrictor endothelin-1 (132, 133). This decrease in vasodilatory signaling coupled 
with an increase in vasoconstriction signaling is an underlying contributing factor to the 
increase in blood pressure associated with PE.  
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Chapter 2 
 
The RNA Binding Protein LIN28 
 
Introduction to LIN28 
 LIN28 is an evolutionarily conserved RNA binding protein that was originally 
discovered using mutagenesis screens investigating heterochronic genes in C. elegans, 
where it was shown to play a vital role in the regulation of developmental changes 
between larval stages (134, 135). Since the time of its discovery, LIN28 has been found 
to regulate development and pluripotency. For instance, LIN28 is highly expressed in 
ESCs and is used in the reprogramming of somatic cells into induced pluripotent stem 
cells (iPSCs), while it is typically downregulated in terminally differentiated cells (136-
139). In C. elegans, LIN28 exists as a single paralog whereas in all vertebrates, LIN28 
exists in two paralogs: LIN28A and LIN28B, both of which function as RNA binding 
proteins and likely arose from an ancestral gene duplication (140, 141). LIN28A and 
LIN28B share 65% sequence homology, with the highest degree of homology existing 
within  the cold shock domain (CSD) and cysteine cysteine histidine cysteine zinc knuckle 
domain (CCHC), two RNA binding domains which are present on both paralogs (134, 
142, 143). However, human LIN28B is approximately 41 amino acids larger than LIN28A, 
and it contains two putative nuclear localization signals: one in the region between the 
CSD and the CCHC domains, and one at the extended C-terminus of the protein (Figure 
3) (144, 145). Furthermore, LIN28B exists in humans as two isoforms, with one being 
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found predominantly in the placenta and undifferentiated tissues, and the other being 
found in fetal liver and non-tumor liver tissues (141). 
The most well-understood pathway of LIN28A and LIN28B involves their regulation 
of the Let-7 family of miRNAs. However, it is important to note that, while LIN28A and 
LIN28B inhibit the maturation of Let-7, they themselves are also targets of Let-7, a highly 
conserved cellular regulatory process known as the LIN28/Let-7 bistable switch (Figure 
3). Therefore, it is important to keep in mind that in cell lines/tissues in which LIN28A 
and/or LIN28B expression is high, Let-7 expression is low, and when Let-7 expression is 
high, LIN28A and LIN28B expression are low. 
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Figure 3. Schematic representation of LIN28A and LIN28B protein. 
 
A. Human LIN28A and LIN28B both contain the cold shock and the CIS-CIS-CIS-HIS 
RNA binding domains, however LIN28B is slightly larger than LIN28A. B. In less 
differentiated tissues, such as ESCs and trophoblasts, LIN28A and LIN28B are 
abundantly expressed while let-7 expression is reduced, whereas in terminally 
differentiated cells, LIN28A and LIN28B expression are reduced, and Let-7 is abundantly 
expressed.  
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Regulation of Let-7 by LIN28A and LIN28B 
 The Let-7 family of miRNAs consists of 12 different miRNAs and is a conserved 
family of tumor suppressors that function to regulate cellular differentiation and 
proliferation through inhibition of RAS, MYC, and Hmga2 (146, 147). Loss of expression 
of Let-7 can result in the cell adopting a less differentiated state, such as what is observed 
in many cancers (148). LIN28A and LIN28B bind an evolutionarily conserved GGAG motif 
in pre-let-7, thereby preventing its maturation (149). This bistable LIN28/Let-7 switch is 
by far the most studied cellular function of LIN28 and Let-7. However, it is important to 
note that LIN28A and LIN28B have also been shown to promote translation of mRNA, 
which will be further discussed later (150-152). While LIN28A and LIN28B are structurally 
very similar, they function to inhibit the maturation of Let-7 by distinct mechanisms. 
 LIN28A has been shown to inhibit the maturation of both pri-Let-7 and pre-Let-7 
transcripts. LIN28A can function in the nucleus by co-transcriptionally binding pri-Let-7 
miRNA transcripts. This binding of LIN28A to the primary transcript is thought to physically 
prevent further processing by DROSHA, and therefore preventing maturation of Let-7 
(153). More abundantly, LIN28A can function in the cytoplasm to inhibit the maturation of 
pre-Let-7 transcripts. The recognition and inhibition of maturation of pre-Let-7 requires 
both the CSD and the CCHC domain of LIN28A (144). Through interactions of these 
domains with the terminal loop of precursor Let-7 transcripts, LIN28A recruits the terminal 
uridylyltransferase (TUTase4/Zcchc11 and/or TUTase7/Zcchc6) which results in 
oligouridylation of the pre-Let-7 transcript (Figure 4). The oligouridylation of pre-Let-7 
leads to rapid degradation of the miRNA transcript, thereby preventing the final maturation 
by DICER (154-156). 
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 LIN28B is typically expressed in the nucleus due to the functional nuclear 
localization signal on the C-terminal end of the protein. While some in vitro studies have 
shown that LIN28B has the capacity to recruit the uridylyltransferase Zcchc11 and 
Zcchc6, knockdown of Zcchc11 in cell lines that express only LIN28B, and not LIN28A, 
does not result in an increase in Let-7 expression (145, 154). Furthermore, Zcchc11 is 
typically found only in the cytoplasm, which further indicates that LIN28B exerts its 
inhibitory regulation of Let-7 through a different mechanism than LIN28A (157). In fact, 
RNA immunoprecipitation and immunohistochemical analyses of LIN28B indicates that 
LIN28B has a very high affinity for Let-7 primary transcripts and that it binds and 
sequesters the primary transcripts in the nucleolus, where the miRNA processing 
machinery is not present (Figure 4) (145).  
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Figure 4. Mechanism of Let-7 repression by LIN28A and LIN28B.  
 
LIN28B binds to primary Let-7 transcripts and sequesters them in the nucleolus, away 
from the miRNA processing machinery. Conversely, LIN28A binds pre-Let-7 miRNA 
transcripts in the cytoplasm to prevent maturation by DICER and associates with 
TUTase4 and TUTase7 to polyuridylate and tag the transcript for degradation.  
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Gene regulation by LIN28A and LIN28B independent of Let-7 
 While regulation of Let-7 by LIN28A and LIN28B is very important and well-
understood, it is important to note their Let-7 independent functions. PAR-clip analyses 
have revealed that LIN28A and LIN28B bind over 3,000 mRNA transcripts, and this 
interaction leads to a moderate increase in the protein abundance (158). Furthermore, 
CLIP-seq analyses of ESCs and human somatic cells stably transfected with LIN28 reveal 
that LIN28 binds to mRNA transcripts at GGAGA motifs, directly regulates the protein 
expression level of RNA binding proteins, and regulates splicing factor abundance, with 
changes in LIN28 levels resulting in widespread changes in alternative splicing (159). In 
addition to the GGAGA motif, it has been shown that LIN28A and LIN28B recognize an 
‘A’ bulge, which is flanked by two G:A base pairs on mRNA transcripts. Recognition of 
this motif, which is embedded in the secondary structure of the mRNA transcript, results 
in association with LIN28A or LIN28B and increased translation of the transcript (160). 
However, it has also been shown that LIN28A, through recognition of conserved motifs in 
the stem loop of some mRNA secondary structures, can repress translation of mRNAs 
that are destined for the endoplasmic reticulum, thus reducing the translation of 
transmembrane and secreted proteins (161). 
While many different gene types are targeted by LIN28A and LIN28B, a large 
portion of the genes are related to cell-cycle progression and promote cellular growth and 
survival. In addition to regulation of alternative splicing and splicing factor abundance, 
LIN28A has been shown to directly bind to the mRNA transcript of IGF-2 in skeletal 
muscle precursors, resulting in enhanced translation of the IGF-2 protein (152). It has 
previously been shown that LIN28A and LIN28B can recruit RNA helicase A, which, 
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through interactions with the C-terminus of LIN28, assists in the remodeling of 
ribonucleoprotein interactions leading to increased translation, which could 
mechanistically explain the LIN28A and LIN28B induced increase in protein translation 
(150). In fact, deletion of the C-terminal end LIN28, while leaving the RNA binding domain 
intact, results in decreased protein translation (150). Furthermore, it is important to note 
that LIN28B protein has been shown to bind and enhance translation of its own mRNA, 
thus further increasing its own expression level (158, 159). This feed-forward mechanism 
plays a part in maintaining high levels of LIN28B, further promoting genes associated with 
cell-cycle progression and cellular growth. However, further studies are warranted to 
validate the abundant targets of LIN28A and LIN28B, and to determine their precise role 
in normal and pathological conditions. 
Elegant studies using transgenic and knockout animals have provided more insight 
into Let-7 independent gene regulation by LIN28A and LIN28B. For instance, mice with a 
skeletal muscle specific deletion of LIN28A display insulin resistance and impaired 
glucose tolerance, notwithstanding any changes in Let-7 expression, while transgenic 
mice overexpressing LIN28A are larger and have increased organ sized despite no 
change in Let-7 expression in the respective organs (162, 163). These studies, along with 
numerous other in vitro and in vivo studies, indicate that LIN28A and LIN28B play a major 
role in growth and metabolism. 
 
Regulation of cellular growth and metabolism by LIN28A and LIN28B 
 In recent years it has become well-established that LIN28A and LIN28B play a 
major role in cellular metabolism, as well as proliferative growth. For instance, repression 
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of Let-7 by LIN28A and LIN28B has been shown to enhance mTOR signaling, resulting 
in increased biogenesis of ribosomes and increased translation, while LIN28A has been 
shown to directly bind the transcripts of many ribosomal peptides, further increasing 
protein abundance and cellular growth (164-166). Also, through the repression of Let-7, 
LIN28A and LIN28B can upregulate the RAS, Myc, and PI3K-AKT pathway, all of which 
result in increased cellular metabolism (162, 167). Furthermore, and again through the 
regulation of Let-7, LIN28A and LIN28B can increase the expression of Hmga2, which 
represses the cyclin dependent kinase inhibitor p16, and thus, promotes cellular 
proliferation and survival (168, 169). Moreover, through regulation of the PI3K-mTOR 
pathway, mice genetically engineered to overexpress LIN28A or LIN28B have increased 
body size and length, in addition to increased glucose metabolism and insulin sensitivity 
accompanied by a resistance to obesity and diabetes (162, 163). Taken together, it is 
clear that both LIN28A and LIN28B, whether directly or indirectly through its regulation of 
the Let-7 family of miRNAs, plays a pivotal role in promoting cellular growth, proliferation, 
and metabolism.  
 
Upstream regulation of LIN28A and LIN28B 
 The regulation of LIN28A and LIN28B by the Let-7 family of miRNAs is well 
characterized, however relatively little is known about the upstream transcriptional control 
of their expression. The upstream regions of LIN28A and LIN28B have many predicted 
transcription factor binding sites, although the vast majority have yet to be characterized 
and validated in vitro. High resolution CHIP-seq analyses have revealed that the 
pluripotency transcription factors Sox2, Nanog, Oct4, and Tcf3 associate with the 
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promoter region of LIN28A, thus driving its expression (170). In addition to promoting the 
transcriptional expression of LIN28A, Sox2 can form protein-protein interactions with 
LIN28A in the nucleus, a process in which further promotes pluripotency (171, 172). 
LIN28A and LIN28B have also been shown to be upregulated in response to TGFβ, 
potentially through the repression of histone methyltransferases and/or the upregulation 
of Smad proteins which interact with a Smad binding element in the promoter region of 
LIN28B, thus driving its expression (173, 174). Furthermore, bioinformatic analysis 
reveals a conserved NF-κB binding element within the LIN28B gene, which results in 
rapid induction of LIN28B expression following activation of NF-κB signaling (175). Lastly, 
CHIP-seq analyses have revealed that the growth factor Myc binds to the upstream 
promoter region of LIN28B, resulting in robust expression (176). It is important to note 
that, while regulating many similar functions such as cellular growth, metabolism, and 
reprogramming, LIN28A and LIN28B appear to be transcriptionally regulated by distinct 
mechanisms. Additional studies are warranted to further elucidate the precise upstream 
regulatory mechanisms of these genes.  
 
LIN28A and LIN28B in embryogenesis and pluripotent stem cells 
 During early embryogenesis, LIN28A protein expression is attained through 
maternal inheritance from the oocyte (177). In the mouse, LIN28A is highly expressed in 
nucleoli precursors of the 2-, 4-, and 8-cell stage, and is very highly expressed in the 
mature nucleoli of the blastocyst. However, in non-human primate embryogenesis, 
LIN28A is observed to be expressed in the nucleoli of the outer blastomeres, suggesting 
a different pattern of expression amongst species. Nevertheless, this compartmentalized 
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expression is speculated to regulate the maturation of nucleoli prior to the activation of 
the embryonic genome (177, 178). Upon activation of the embryonic genome, both 
LIN28A and LIN28B are highly expressed in the inner cell mass, which is also true for in 
vitro cultured ESCs. Furthermore, RNAi mediated knockdown of LIN28A in ESCs results 
in defects in the cells proliferative capacity, while overexpression increased the rate of 
cell division and accelerated the formation of iPSCs (137, 179). However, considering 
LIN28A or LIN28B knockout mice develop through the blastocyst stage relatively normally 
in utero, it appears that LIN28A and/or LIN28B are not absolutely required for 
pluripotency, at least in vivo (180). Taken together, these data indicate that LIN28A and 
LIN28B play a vital role in early embryonic development, as well as in the maintenance 
of pluripotent stem cells.  
 
LIN28A and LIN28B in cancer and cellular invasion 
 Many of the proliferative, migratory, and invasive pathways that are activated 
during normal embryogenesis and trophoblast invasion during pregnancy are exploited 
by cancer cells during growth and metastasis (181, 182). Considering the major role of 
LIN28A and LIN28B in the regulation of cellular growth, proliferation, metabolism, and 
stemness, it is no surprise that the reactivation of LIN28A and/or LIN28B and subsequent 
loss of Let-7 has been reported in many cancers including breast, cervical, colon, 
esophageal, gastric, and liver, amongst many others (183-186). Furthermore, the degree 
of LIN28A and/or LIN28B reactivation and Let-7 loss is highly correlated with disease 
progression and poor prognosis (187). It has been postulated that the increased 
LIN28A/LIN28B signaling in these cancers results in high expression levels of many 
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oncogenes, including K-RAS, c-Myc, and Hmga2, through repression of Let-7 signaling. 
In addition, high levels of LIN28A and LIN28B have been observed in cancer stem cells 
and have been shown to enhance the formation of these cells, further implicating LIN28 
in disease progression (188, 189).  
Prior to EVT invasion into the maternal decidua, placental trophoblasts undergo 
an EMT, resulting in the ability to migrate and invade (190). In a similar manner, cancers 
cells must undergo an epithelial to mesenchymal transition prior to local invasion of 
surrounding tissue in a process that has been shown to be induced by expression of 
LIN28A (188). EMT is characterized by the loss of E-cadherin expression with a parallel 
increase in mesenchymal transcription factors such as Snail, Slug, and Twist. In fact, 
many studies of multiple cancer types have shown that LIN28A and LIN28B promotes 
cancer invasion through promotion of EMT, while Let-7 inhibits invasion (191). LIN28A 
and LIN28B promote invasion through the repression of Let-7, which in turn leads to an 
increase in the expression of Hmga2, which promotes EMT through the upregulation of 
Snail and Slug and downregulation of E-cadherin (192). Furthermore, LIN28A and 
LIN28B have been shown to interact with and promote the translation of Hmga1, another 
factor which also promotes EMT, while also interacting with E-cadherin mRNA and 
repressing its translation (161, 165, 193). Based on these findings, it is clear that LIN28A 
and LIN28B play a major role in EMT and cancer cell invasion in a process that parallels 
that of initial trophoblast invasion during pregnancy.  
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Gap in knowledge and purpose of this dissertation 
 LIN28A and LIN28B are RNA binding proteins that are highly expressed in ESCs 
and other less differentiated cells and were initially discovered as regulators of Let-7 
miRNA maturation. However, LIN28A and LIN28B are also expressed in the developing 
embryo, fetal tissues, the testes, the placenta, and in cancer cells. In the years since their 
discovery, it has been shown that, in addition to the regulation of Let-7, these proteins 
play a major role in mRNA translation and the regulation of splicing factor abundance. 
Through these interactions with many different miRNAs and mRNAs, LIN28A and LIN28B 
function to regulate numerous different cellular processes, such as cellular metabolism, 
growth, proliferation, and invasion. 
 PE is a disease of pregnancy that is characterized by the onset of hypertension 
and proteinuria after 20 weeks of gestation. In addition to the short-term unfavorable 
maternal health effects caused by PE, there are many long-term adverse outcomes that 
affect both the mother and child. Epidemiological studies have indicated that long-term 
maternal adverse outcomes include prolonged hypertension and kidney disease. On the 
other hand, long-term health problems for the child include a much greater likelihood of 
developing hypertension, kidney disease, and metabolic disorders such as diabetes.  
Although the clinical manifestations of PE do not typically arise until >20 weeks gestation, 
the underlying pathological changes that lead to the development of PE are thought to 
begin much earlier.  
 Early in pregnancy, upon implantation of the blastocyst to the maternal decidua, 
invasive EVTs begin invading and remodeling the maternal spiral arteries. This 
remodeling results in a phenotypic change of the arteries from a high pressure, low flow 
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system, to a low pressure, high flow system that allow for deliver adequate blood to the 
developing placenta and fetus. In PE, due to currently unknown molecular and 
biochemical aberrations, this invasion and remodeling is inadequate, which results in the 
placenta and fetus being exposed to prolonged increasingly hypoxic conditions.  
 Despite the enormous amount of knowledge regarding LIN28, it is not currently 
known which paralog is primarily expressed in the human placenta, and in which placental 
cell types it is expressed. Furthermore, the regulation and pathophysiologic role of 
LIN28A and/or LIN28B in placenta associated disorders, such as PE, has not been 
investigated. To shed light on the role of LIN28A and LIN28B in the placenta in view of its 
predominant placental expression and role in modulating cell metabolism, differentiation, 
growth and invasion, we hypothesized that decreased placental LIN28A and/or LIN28B 
expression impairs trophoblast differentiation and invasion, which could contribute to the 
development of PE. To address this gap in the knowledge, we evaluated: 1) LIN28 
expression in human term placentas and compared LIN28A and LIN28B expression in 
placentas from gestational-aged matched normotensive with preeclamptic pregnancies, 
2) the impact of LIN28 over/under expression on trophoblast invasiveness and 
differentiation, and 3) the role of hypoxia in regulating LIN28 expression in trophoblasts. 
Based on our findings, we propose the hypothesis that deficiencies in LIN28B may be a 
contributing factor in the initial impaired invasion observed in PE and in the development 
of the long-term adverse health outcomes associated with the disorder.  
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Chapter 3 
 
 Materials and Methods 
 
Ethical approval 
Collection of 15 human placentas from normotensive pregnancies and 13 human 
placentas from PE affected pregnancies was approved by the Institutional Review Board 
(IRB) of the University of South Florida (protocol #00015578) after obtaining informed and 
written patient consent. Additional total RNA from 6 normotensive and 6 PE pregnancies 
was provided by Dr. Ananth Karumanchi, Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, MA. Placentas from the first trimester (7 weeks gestation and 8 
weeks gestation, n=2) and early pregnancies (20 weeks gestation, n=2) were obtained 
from voluntary terminations of uncomplicated pregnancies under the same institutional 
approval. The clinical characteristics of the patients used for this study are shown in Table 
1 and Table 2. 
 
Criteria for inclusion in the study 
For the samples used in this study, preeclampsia was diagnosed according to 
criteria established by The American College of Obstetricians and Gynecologists (194).  
According to these guidelines, preeclampsia is defined by blood pressure that is 
>140mmHg systolic or >90mmHg diastolic, accompanied by proteinuria, in a woman who 
was normotensive throughout the first 20 weeks of gestation.  
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Placental tissue collection 
Following delivery, the placenta was placed on ice until dissection. For RNA and 
protein analysis, tissue samples were excised from the fetal compartment of the placenta, 
placed in 15 ml conical tubes, and frozen on dry ice. The tissues were then stored at -
80oC until further use. For immunohistochemistry, tissue samples were excised from the 
fetal compartment of the placenta, fixed overnight in 10% formalin, followed by routine 
paraffin-embedding procedure. Paraffin blocks were stored at room temperature until 
further use.  
 
Isolation and culturing of primary DCs 
Term DCs were isolated, as previously described from uncomplicated pregnancies 
undergoing repeat cesarean delivery at term under Yale human investigation committee 
approval (#22674) (195). Briefly, after removal of the amnion from placental membranes, 
decidua parietalis was scraped from the chorion, whereas decidua basalis was scraped 
from the placental surface distal to the intervillous space. The scraped tissues were each 
digested by collagenase-deoxyribonuclease, purified on a Percoll gradient, grown to 
confluence, and passaged until found to be >99% free of CD45+ cells by flow cytometry 
(195). Confluent term DCs were then primed in serum-containing medium with E2 + MPA 
(Sigma-Aldrich, St. Louis, MO) for 7 days to maintain their decidualization properties. 
Total RNA was then extracted from confluent DCs and stored at -80oC for use in further 
studies. 
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Isolation and culturing of primary CTs 
 Isolation of CTs from placentas obtained from uncomplicated pregnancies and 
repeat cesarean deliveries at term using procedures approved by the Yale human 
investigation committee (#22674) was performed as described (195, 196). Briefly, villous 
tissue was initially digested with trypsin/deoxyribonuclease I and centrifuged on a 
discontinuous Percoll gradient (50%/45%/35%/30%). Cells migrating to the 35%/45% 
Percoll interface were recovered by centrifugation and were immunopurified using 
negative selection by simultaneous treatment with mouse anti-human CD9 antibody, 
mouse anti-human CD45 antibody, and then goat anti-mouse IgG-conjugated 
DynaBeads (Life Technologies, Grand Island, NY), yielding CTs with >98% purity on the 
basis of immunocytochemical and flow cytometric analysis. The decidua basalis layer 
was trimmed off before digestion, leaving primarily villous tissue for CT isolation. Total 
RNA was then extracted and stored at -80oC for further use. 
 
Isolation and culturing of primary STs 
 STs were obtained by spontaneous differentiation of CTs after 72 hours of culture, 
as previously described (197). Briefly, CTs were isolated from villous placental tissue at 
term followed by Percoll gradient centrifugation, as described above. Following isolation, 
CTs were grown in DMEM-F12 supplemented with 10% FBS (Gibco Laboratories, 
Gaithersburg, MD) for 72 hours to allow for spontaneous syncytialization. Total RNA was 
then isolated and stored at -80oC for use in later analyses.  
 
Immunohistochemistry 
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Immunohistochemistry was performed as previously described (198). Briefly, 5-µm 
paraffin sections from human placentas were incubated overnight at 56oC then 
deparaffinized in xylenes and rehydrated by graded ethanol washes. Antigen retrieval 
was performed by boiling in 10 mM citric acid, pH 6.0 for 15 minutes. The sections were 
then incubated in 3% H2O2 for 12 minutes to quench endogenous peroxidase activity 
followed by blocking in 5% normal goat serum for 30 minutes at room temperature. The 
sections were subsequently incubated overnight in a humidified chamber with the primary 
antibody (rabbit anti-LIN28B, 40μg/ml, Abcam, ab71415 RRID:AB_2135050) diluted in 
5% normal goat serum. LIN28B immunoreactivity was detected using a biotinylated goat 
anti-rabbit secondary antibody (Vector Laboratories, BA-1000 RRID:AB _2313606) 
together with the avidin-biotin-peroxidase complex (Vectastain ABC kit, Vector 
Laboratories, pk6200 RRID:AB_2336826) followed by 3,3’-Diaminobezidine (DAB; 
Vector Laboratories, sk-4100 RRID:AB_2336382) incubation as a substrate. The sections 
were then counterstained with hematoxylin (Vector Laboratories, H3404 
RRID:AB_2336843), rehydrated, and covered with a glass coverslip for later analysis.  
 
Quantification of immunohistochemistry 
LIN28B immunoreactivity was semi-quantitatively evaluated using the histology 
score (H-score) method, as previously described (199). Briefly, three different high-power 
fields for each section were imaged and scored by three separate blinded individuals 
using the following scale: 0+ (no staining or weak staining), 100+ (moderate and 
detectable staining), 200+ (distinct staining). The average score for each section was 
considered the H-score.  
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Cell culture  
 BEWO cells (ATCC CCL-98, Manassas, VA, USA) were cultured in F-12K medium 
supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA). 
JEG3 cells (ATCC HTB-36, Manassas, VA, USA) were grown in MEM (GIBCO, Waltham, 
MA, USA) supplemented with 10% FBS. HTR-8/SVneo (ATCC CRL-3271, Manassas, 
VA, USA) cells were cultured in RPMI-1640 supplemented with 5% FBS. Cell lines were 
maintained at 37oC and 5% CO2.  
 
Cell line authentication 
The JEG3, BEWO, and HTR8/SVneo cells were authenticated by short tandem 
repeat (STR) analysis through ATCC. For authentication, ATCC amplifies 17 short 
tandem repeats, plus Amelogenin, for comparison to their database of authenticated cell 
lines. Each of the cell lines used in this study were a 100% match to the STR data in the 
ATCC database (appendix 1). 
 
Transfections 
 JEG3 cells were transfected with scrambled shRNA or an shRNA targeting LIN28B 
(OriGene Technologies TG311156, Rockville, MD, USA) using Lipofectamine 2000 
following the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). 
HTR8/SVneo cells were transfected with green fluorescent protein (GFP) or 
pFRT/FLAG/HA-DEST LIN28B plasmid, a gift from Thomas Tuschl (Addgene 43798, 
Cambridge, MA, USA) using 25kD linear polyethylenimine (Polysciences 23966, 
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Philadelphia, PA, USA) (158). Briefly, 105 cells/well were seeded in triplicate in a 12-well 
plate, plasmids were diluted in sterile water followed by the addition of NaCl (final 
concentration of 150mM) and polyethylenimine (final concentration of 0.05µg/μl). The 
mixture was vortexed, incubated at room temperature for 15 minutes and 500µl of RPMI 
containing 5% FBS medium was added, and the transfection mixture was pipetted onto 
cells in each well. 
 
Cell proliferation analysis 
 Cell proliferation was measured using the WST-1 cell proliferation reagent (Sigma 
Aldrich, St. Louis, MO, USA), as previously described (200). Briefly, JEG3 or 
HTR8/SVneo cells were transfected as indicated above. 72 hours following transfection, 
the medium was replaced with 90µl fresh medium and 10µl WST-1 reagent. Following 
incubation at 37oC for 1 hr, the absorbance was measured at 450nm and 690nm, with the 
latter being used as the reference wavelength. The relative proliferation was then 
determined for each treatment.  
 
Hypoxia experiments 
 BEWO or JEG3 cells were seeded in 12-well plates and allowed to attach overnight 
while being housed under normal culture conditions (21% oxygen, 5% CO2) at 37o C in 
standard CO2 water-jacketed cell culture incubators. The following day, the medium was 
replaced with fresh medium and the ‘normal culture condition’ (21% oxygen) cells were 
placed back in the same incubator. The cells that were to be subjected to hypoxic 
conditions (1% oxygen) were placed in a polycarbonate, airtight hypoxia incubator 
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chamber (StemCell Technologies, Catalog #27310) and flushed with a gas mixture of 1% 
oxygen, 5% CO2, and 94% nitrogen for 10 minutes at a flow rate of 20L/minute. The 
sealed chamber was then placed back in the same 37oC water-jacketed incubator. The 
chamber was flushed at a flow rate of 20L/minute for 10 minutes every 24 hours for the 
duration of the experiment. Oxygen levels were monitored using a portable oxygen meter 
(KKmoon #803) and averaged 1.13 ± 0.14% oxygen throughout the duration of the 
experiments.  
 
RNA extractions 
 Placental samples were suspended and homogenized in Qiazol to isolate total 
RNA. After experimental cell incubation, cultured cells were lysed using Qiazol. Total RNA 
was extracted using the miRNeasy mini kit according to the manufacturer’s protocol 
(Qiagen).  
 
Protein extractions  
For protein isolation, placental specimens were homogenized on ice in lysis buffer 
containing 20 mM Tris-HCl, 124 mM NaCl, 4 mM EDTA, 0.4% CHAPS, 20 mM HEPES, 
200 μM bestatin, 60 μM E-64, 40 μM leupeptin, 600 μM aporotinin, 2 mM NaF, 2.3 mM 
sodium molybdate, 2 mM sodium orthovanadate, and 1mM b-glycerophosphate. The 
homogenized samples were then incubated on ice for 20 minutes followed by 
centrifugation for 10 minutes at 21,000xg. Each resulting supernatant was transferred to 
a new tube and stored at -80oC for subsequent immunoblotting. For protein isolation from 
cell culture experiments, collected cells were pelleted then resuspended in lysis buffer 
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and incubated on ice for 20 minutes, followed by centrifugation for 10 minutes at 
21,000xg. The supernatant was then stored at -80oC for later immunoblotting.   
 
Immunoblotting  
 Protein lysates were fractionated by SDS-PAGE as previously described (201). 
Following fractionization, the lysates were transferred to a nitrocellulose membrane and 
subsequently blocked for 1 hour at room temperature in Odyssey blocking buffer (LI-
COR). The membranes were then incubated overnight with LIN28B (2μg/ml, Abcam, 
ab71415 RRID:AB_2135050) and α-tubulin (0.35μg/ml, Cell Signaling Technology, 
2144S RRID:AB_2210548) primary antibodies followed by probing with the secondary 
antibody IRDye 680 goat anti-rabbit (0.2μg/ml, LI-COR, 926-68073 RRID:AB_10954442). 
The resulting immunoblots were scanned and quantitatively assessed using the Odyssey 
infrared imaging system (LI-COR). 
 
qRT-PCR 
 cDNA was synthesized by reverse transcription of 500 ng of total RNA using M-
MuLV reverse transcriptase per the manufacturer’s protocol (New England Biolabs, 
M0253L). After reverse transcription, relative mRNA expression levels were measured by 
using TaqMan Fast Advanced Mastermix (Life Technologies, 4366072) and TaqMan 
qPCR primers/probes (ThermoFisher Scientific, LIN28A: HS_00702808_s1, LIN28B: 
HS_01013729_m1, TNFα: HS_01113624_g1, SYN-1: HS_01926764_u1, ITGβ4: 
HS_00236216_m1, ELABELA: HS_04274421_m1) with the Quantstudio 3 qPCR 
machine (Applied Biosystems). For miRNA expression analysis, 50ng of total RNA was 
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reverse transcribed using a TaqMan miRNA reverse transcription kit (Applied Biosystems, 
4366597) and miRNA specific TaqMan primers/probe sets (ThermoFisher Scientific, miR-
516a: 002416, miR-516b: 001150, miR-517a: 002402, miR-518c: 002401, miR-519d: 
002403, Let-7g: 478580, U18: 001204) as previously described (202). The experimental 
results were then analyzed using the delta-delta Ct method.   
 
Scratch wound assays  
 HTR8/SVneo cells were seeded in a 24-well dish and transfected the following day 
with a plasmid encoding either GFP or LIN28B. 72 hours later, as previously described, 
a single scratch wound was established in each well using a P-200 pipette tip (203). The 
well was then washed thoroughly with sterile PBS. The wounds were then photographed 
to establish the baseline for later comparison. After 24 hours incubation in the full medium, 
the cultured cells were fixed in PFA and stained with crystal violet and re-photographed 
for analysis of wound closure. 
 
Trans-well migration assays 
 Trans-well migration assays were performed as previously described (204, 205). 
Briefly, HTR8/SVneo cells were seeded in a 12 well dish and transfected the following 
day with a plasmid encoding GFP (control) or LIN28B. After 72 hours, 2x104 transfected 
cells were seeded in serum free RPMI in the upper chamber of a Matrigel coated trans-
well insert (insert: Falcon, 353097, Matrigel: Corning 354744). RPMI containing 5% FBS 
was placed in the lower chamber. 24 hours later, non-migrated cells were removed from 
the upper chamber using a cotton tipped swab. The remaining migrated cells were fixed 
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with PFA and then stained with crystal violet and imaged. The number of migrated 
cells/field was counted to determine the migration.  
 
Statistical analyses  
 All results are presented as means ± SEM. All data were tested for normality and 
equivalence of variance to determine the appropriate statistical tests. One-way ANOVA 
with Tukey’s post hoc test was performed for multiple group analyses. Multiple two-way 
Students t-tests with Holm-Sidak correction for multiple comparisons were performed to 
determine changes in mean gene expression. For analysis of demographic data, 
Students t-tests, chi-square test, or Fisher’s exact test were used to determine significant 
differences in the cohorts. All statistical analyses were performed using GraphPad Prism 
7 software and results were considered significant when adjusted p<0.05. 
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Table 1. Available demographic data and clinical characteristics of the 15 normal and 
13 PE subjects obtained from the University of South Florida for this study.  
 
Characteristic Normal n=15 Preeclampsia n=13 
Maternal Median age 25 [19-36] 26 [19-33] 
Gravida 2 [1-12] 2 [1-4] 
Median Gestational 
Age 39 [37-40.1] 37.6 [37.0-40.3] 
BMI 32.8 [24-62.6] 31.3 [29-77.2] 
Maternal Race   
      White 3 [20%] 6 [46.2%] 
      Black 5 [33.3%] 3 [23.1%] 
      Asian 1 [6.7%] 0 [0%] 
      Hispanic 4 [26.7%] 4 [30.8%] 
      Unknown 2 [13.3%] 0 [0%] 
Cigarette Use 2 [13.3%] 2 [15.4%] 
cHTN 1 [6.7%] 2 [15.4%] 
DM (Gestational DM) 4 (2) [26.7%] 2 (1) [15.4%] 
Mode of Delivery   
      Vaginal 4 [26.7%] 4 [30.8%] 
   Cesarean section 11 [73.3%] 9 [69.2%] 
Indication for C/S   
      Failure to Progress 0 [0%] 4 [30.8%] * 
      Other 0 [0%] 1 [7.7%] 
      Repeat 9 [60%] 2 [15.4%] 
Fetal Sex   
      Male 4 [26.7%] 8 [61.5%] 
      Female 11 [73.3%] 5 [38.5%] 
Fetal Weight (g) 3390 [2590-4440] 3380 [1965-3960] 
*Indicates p<0.05 vs normal cohort 
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Table 2. Available demographic data and clinical characteristics of the 6 normal and 6 
PE subjects obtained from the Harvard Medical School for this study.  
 
Characteristic Normal n=6 Preeclampsia n=6 
Maternal Median age 35 [23-39] 25 [23-37] * 
Gravida 2.6 [1-6] 1.5 [1-4] 
Median Gestational Age 39 [39-40] 34 [30-39] * 
BMI 24.1 [19.5-29.3] 26.9 [19.6-35.4] 
Maternal Race   
      White 6 [100%] 4 [66.7%] 
      Asian 0 [0%] 2 [33.3%] 
Cigarette Use 0 [0%] 1 [16.7%] 
cHTN 0 [0%] 1 [16.7%] 
DM (Gestational DM) 0 (0) [0%] 0 (0) [0%] 
Mode of Delivery   
      Vaginal 0 [0%] 2 [33.3%] 
      Elective C/S 6 [100%] 4 [66.7%] 
Indication for C/S   
      Failure to Progress 0 [0%] 0 [0%] 
      Other 3 [50.0%] 2 [33.3%] 
      Repeat 3 [50.0%] 2 [33.3%]  
Fetal Sex   
      Male 2 [33.3%] 5 [83.3%]  
      Female 4 [66.7%] 1 [16.7%] 
Fetal Weight (g) 3917 [3240-4420] 2217 [1045-3905] * 
*Indicates p<0.05 vs normal cohort 
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Chapter 4 
 
Decreased LIN28B in Preeclampsia Impairs Human Trophoblast Differentiation 
and Migration 
Introduction 
 PE is a life-threatening complication of pregnancy with clinical symptoms that 
include hypertension and proteinuria, and is a leading cause of maternal morbidity 
worldwide (1). In severe cases, PE can result in tonic-clonic seizures and/or hemolysis, 
elevated liver enzymes, and low platelet counts, conditions known as eclampsia and 
HELLP syndrome, respectively (206). Currently, the comprehensive underlying etiology 
of PE is incompletely understood. However, it appears that PE is generally driven due to 
a maternal milieu that is susceptible to hypertension and/or chronic exposure of the 
placenta and developing fetus to prolonged pathologically hypoxic conditions (7, 8, 207).  
 In early human pregnancy, invasive EVTs begin invading the decidual tissue 
following implantation of the blastocyst to the uterine wall. Through several different 
mechanisms, this invasion ultimately results in extensive remodeling of the maternal 
spiral arteries leading to myogenic tone loss and adequate perfusion of the placenta (69, 
77, 208). However, in PE this EVT invasion is impaired, which results in inadequate spiral 
vasculature remodeling and insufficient perfusion of the placenta (97, 98). The resulting 
prolonged hypoxia can result in IUGR and can stimulate the secretion of placentally 
derived factors, such as sFLT-1 and sEng, into the maternal circulation, ultimately 
resulting in systemic endothelial dysfunction and elevation of the maternal blood pressure 
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(104, 105, 209). Furthermore, ST formation and function is known to be impaired by 
hypoxia and is often observed in the placentas of PE affected pregnancies (210, 211).  
 The most extensively characterized function of the RNA binding protein LIN28 is 
its inhibition of the maturation of the Let-7 family of miRNAs. However, LIN28 is also post-
transcriptionally regulated by the Let-7 family. This highly conserved LIN28/Let-7 switch 
plays an integral role in regulation stem cell self-renewal, cellular differentiation, 
embryonic growth, developmental timing, cellular glucose metabolism, and cellular 
invasion (140, 162, 163, 191). In vertebrates, LIN28 exists as two paralogs that share 
approximately 65% sequence identity, with LIN28B being 41 amino acids larger and 
containing a C-terminal nuclear localization signal (145). While LIN28A and LIN28B are 
very similar and share many of the same functions, it is becoming more clear that they 
also have separate functions in the cell. Furthermore, the role of LIN28 in cellular growth, 
invasion, metabolism, and differentiation suggests that it may play a key role EVT 
differentiation and invasion, however their role in the human placenta has yet to be 
investigated. Furthermore, based on these known cellular roles, aberrant expression of 
LIN28 may contribute to the pathogenesis of PE. Therefore, we aimed to evaluate: 1) 
LIN28A and LIN28B expression in human term placentas to determine if there is 
differential expression between the two paralogs, 2) LIN28 expression in placentas from 
gestational-aged matched normotensive with preeclamptic pregnancies, 3) the impact of 
LIN28 over/under expression on trophoblast invasiveness and differentiation, and 3) the 
role of hypoxia in regulating LIN28 expression in trophoblasts. 
 
Results 
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LIN28B is the predominant LIN28 paralog expressed in human term placentas 
 Considering LIN28A and LIN28B may have differing functions within the cell, we 
first set out to determine if either paralog was preferentially expressed in the human term 
placenta. To accomplish this, we isolated total RNA from whole placenta tissue lysates 
and performed qRT-PCR for LIN28A and LIN28B. This analysis revealed that LIN28B 
was expressed ~1300-fold higher than LIN28A, indicating that LIN28B was the 
predominant paralog expressed in the human term placenta (Figure 5A). To confirm and 
expand on these findings, we isolated total RNA from primary cultures of human DCs, 
CTs, and STs collected from normal term placentas and performed qRT-PCR analysis 
for LIN28A and LIN28B. This analysis revealed that LIN28B was expressed ~50, ~750, 
and ~500-fold higher than LIN28A in DCs, CTs, and STs respectively, further confirming 
that LIN28B is the predominantly expressed LIN28 paralog in the human term placenta 
(Figure 5B). 
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Figure 5. LIN28B is the predominant LIN28 paralog expressed in human placentas. 
 
A. qRT-PCR analysis for LIN28A and LIN28B mRNA expression normalized to GAPDH 
in term whole placental tissue lysate. B. qRT-PCR analysis for LIN28A and LIN28B 
mRNA expression normalized to GAPDH in isolated primary human DCs, CTs and STs. 
Results represent means ± SEM. * indicates p<0.05 versus LIN28A   
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LIN28B is expressed significantly higher in CTs and STs compared to DCs in the human 
term placenta 
To determine the precise in situ protein localization of LIN28B in the human term 
placenta, we performed immunohistochemistry for LIN28B on human term placental 
specimens and quantified the expression using an H-score method (199). These 
immunostainings and subsequent quantifications revealed significantly higher levels of 
LIN28B in CTs and STs compared to DCs (Figure 6A-D). Collectively, these findings 
suggested that LIN28B is the predominant paralog expressed in human placentas and its 
expression is primarily in placental versus decidual cell types. In light of these findings, 
we primarily focused on the function, expression, and regulation of LIN28B for the 
remainder of the study.  
 
In situ LIN28B protein is decreased in placentas from PE complicated pregnancies. 
 Given the predominant expression of LIN28B over LIN28A in the human term 
placenta, as well as its major role in cellular proliferation, invasion, and metabolism, we 
next wanted to determine if its expression is reduced in the placentas of PE complicated 
pregnancies. To accomplish this, we performed immunohistochemical staining for 
LIN28B on term placentas from normal and PE complicated pregnancies. Interestingly, 
as shown in Figure 7A-D, LIN28B expression appears greatly reduced in both invasive 
trophoblasts and trophoblasts of the chorionic villi of placental specimens from PE 
affected pregnancies compared to normal pregnancies.  
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Figure 6. LIN28B is expressed significantly higher in CTs and STs compared to DCs 
in the human term placenta 
 
A-C. Representative immunohistochemistry images in term human placenta of invasive 
trophoblasts (A) and villous trophoblasts (B) immunostained for LIN28B or non-immune 
rabbit IgG only control (C). D. H-score analysis for LIN28B protein expression in DCs, 
CTs, and STs of placental specimens from normotensive pregnancies. Scale bar 
represents 35 μm. n= 10 placental sections in (D). Results represent means ± SEM. 
*indicates p<0.05 versus DCs. 
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Figure 7. in situ LIN28B protein is decreased in placentas from PE pregnancies. 
A-D. Representative images of LIN28B immunostaining of invasive trophoblasts (A and 
C) and villous trophoblasts (B and D) in placentas from normotensive pregnancies (A and 
B) and in PE placental tissues (C and D). Scale bar represents 35 μm. 
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LIN28B mRNA and protein expression is reduced in the placenta of PE complicated 
pregnancies 
 To confirm the immunohistochemical findings that suggested LIN28B is reduced 
in the placenta of PE complicated pregnancies, we isolated total RNA and total protein 
from normal and PE affected pregnancies. Subsequent qRT-PCR and immunoblot 
analyses for LIN28B confirmed that both the mRNA and protein expression level was 
significantly reduced in placental tissue from PE complicated pregnancies compared to 
placental tissue from normal pregnancies (Figure 8A-C).  
To investigate whether there is an increase in LIN28A expression to compensate 
for the decrease in LIN28B observed in the placenta of PE affected pregnancies, we also 
performed immunoblot and qRT-PCR analyses for LIN28A protein and mRNA expression 
on the same samples used for analysis of LIN28B expression. These analyses revealed 
no significant change in the already low protein or mRNA expression of LIN28A in 
placental tissue from PE affected pregnancies compared to placenta tissue from normal 
pregnancies (Figure 9A-C). Collectively, these results confirm that both the mRNA and 
protein expression of LIN28B, but not LIN28A, is significantly reduced in placental tissue 
of PE complicated pregnancies, which warrants further investigation into the role of 
LIN28B in pregnancy and PE.  
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Figure 8. LIN28B protein and mRNA is decreased in the placenta of PE complicated 
pregnancies 
 
A. Immunoblot analysis for α-Tubulin and LIN28B from placenta tissue lysates from four 
term normotensive pregnancies and four PE-affected pregnancies. B. Densitometric 
immunoblot analysis for LIN28B normalized to α-tubulin from tissue lysates from 15 
normotensive pregnancies and 13 PE-affected pregnancies. C. qRT-PCR analysis for 
LIN28B mRNA expression normalized to GAPDH in placental lysates from 21 
normotensive pregnancies and 19 PE-affected pregnancies. Results represent means ± 
SEM. * indicates p<0.05 versus normal. 
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Figure 9. LIN28A protein and mRNA expression is unchanged in the placentas of 
PE complicated pregnancies 
  
A. Immunoblot analysis for α-Tubulin and LIN28A from placenta tissue lysates from four 
term normotensive pregnancies and four PE-affected pregnancies. B. Densitometric 
immunoblot analysis for LIN28A normalized to α-tubulin in term placental tissue lysates 
from 15 normal pregnancies and 13 PE-affected pregnancies. C. qRT-PCR analysis for 
LIN28A normalized to GAPDH in term placental tissue lysates from 15 normal 
pregnancies and 13 PE-affected pregnancies. Results represent means ± SEM. 
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The Let-7/LIN28B ratio is increased in the placenta of PE complicated pregnancies 
 The inhibition of Let-7 miRNA maturation by LIN28B has been well documented 
and characterized (145). Therefore, we aimed to test whether the decrease in LIN28B 
expression in the placenta of PE affected pregnancies results in increased Let-7 miRNA 
expression. To accomplish this, we performed qRT-PCR analysis for Let-7g, which is a 
Let-7 family member that has been shown to be highly sensitive to LIN28B expression, 
as well as Let-7a, another member of the Let-7 family of miRNAs (158). As shown in 
Figure 10, the Let-7g/LIN28B and Let7-a/LIN28B ratio trended towards an increase 
(p=0.072 for Let-7g/LIN28B, p=0.077 for Let-7a/LIN28B) in placental tissues from PE 
complicated pregnancies.   
 
LIN28B is highly expressed in syncytial sprouts and invasive EVTs in first trimester human 
placentas  
 Following implantation, human trophoblasts can differentiate into EVTs, which 
invade and remodel the maternal spiral arteries, or STs, which form the syncytial layer of 
the placenta. The population of EVTs includes proliferative proximal EVTs, invasive distal 
EVTs, interstitial EVTs in the interstitial area of the decidua, and endovascular EVTs in 
the maternal spiral arteries, all of which can be detected in first trimester and early 
pregnancy placental sections. Therefore, we performed immunohistochemical staining for 
LIN28B on first trimester and early pregnancy human placental sections to determine the 
precise in situ LIN28B expression pattern among the different trophoblast types. This 
analysis revealed that syncytial sprouts and EVTs in the trophoblastic cell columns in 
anchoring villi displayed stronger LIN28B expression when compared to villous 
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cytotrophoblasts (Figure 11A). Furthermore, LIN28B immunoreactivity gradually 
increased from the proximal (proliferative) EVTs to the distal (invasive) EVTs in the cell 
columns (Figure 11B). Moreover, the strongest LIN28B expression was exhibited in 
interstitial trophoblasts (cytokeratin positive) invading the decidua (vimentin positive) 
(Figure 11 C and D). This pattern of LIN28B expression provides supporting in situ 
evidence for its involvement in the differentiation of trophoblasts towards an invasive 
phenotype and/or syncytialization.  
 
LIN28B increases trophoblast migration and invasion in vitro 
 To complement the in situ immunohistochemistry findings that LIN28B is highly 
expressed in invasive EVTs invading the maternal decidua with functional in vitro 
experiments, we overexpressed LIN28B in a first trimester human trophoblast cell line 
(HTR8/SVneo) and tested its effect on cell migration and cell invasion, using an 
established scratch wound assay and Matrigel invasion assay, respectively (203-205). As 
shown in Figure 12, overexpression of LIN28B resulted in a significant increase in 
HTR8/SVneo migration when compared to control. Furthermore, overexpression of 
LIN28B resulted in an increase in cell invasion through the Matrigel, however it did not 
reach statistical significance (p=0.053, Figure 13). Collectively, these analyses indicate 
that LIN28B plays a major role the in regulation of trophoblast migration and invasion, 
both in vitro and in human tissue. 
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Figure 10. The Let-7/LIN28B ratio trends towards an increase in the placenta of PE 
complicated pregnancies 
 
A. Let-7g/LIN28B protein ratio determined by qRT-PCR analysis for let-7g normalized to 
U18 and LIN28B immunoblot normalized to α-tubulin in placental lysates from 
normotensive pregnancies and PE-affected pregnancies. B. Let-7a/LIN28B protein ratio 
determined by qRT-PCR analysis for let-7a normalized to U18 and LIN28B immunoblot 
normalized to α-tubulin in placental lysates from normotensive pregnancies and PE-
affected pregnancies. Results represent means ± SEM. 
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Figure 11. LIN28B is highly expressed in syncytial sprouts and invasive 
trophoblasts in first trimester placentas  
A-C. Representative images of immunohistochemical staining for LIN28B with nuclear 
hematoxylin counterstain in human first trimester placental sections. LIN28B is highly 
expressed in the syncytial sprouts of chorionic villi (black arrows, A). LIN28B expression 
gradually increases from proliferative proximal EVTs (PEVTs) to distal invasive EVTs 
(DEVTs) in placental cell columns (B). LIN28B expression is lowest in PEVTs and 
increased in invasive interstitial trophoblasts (black arrows) invading the maternal decidua 
(red arrowheads) in anchoring villi (C). D. Representative serial section of tissue shown 
in (C) double immunostained for decidual cell marker vimentin (pink) and trophoblast 
marker cytokeratin-7 (brown). Red arrowheads and black arrows in (D) correspond to red 
arrowheads and black arrows in (C). Scale bar represents 35µm.  
  
62 
 
 
Figure 12. LIN28B increases HTR8/SVneo cell migration 
 
A. Top: representative images at the time of scratch wound application of HTR8/SVneo 
cells transfected with GFP (control) or LIN28B. A. Bottom: representative images of 
cells stained with crystal violet 24 hours after scratch wound application. B. 
Quantification of migration 24 hours after scratch wound application. Results represent 
means ± SEM. *indicates p<0.05 versus control.  
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Figure 13. LIN28B increases HTR8/SVneo cell invasion 
 
A. Representative crystal violet staining image of HTR8/SVneo cells that migrated 
through Matrigel 72 hours after transient transfection with GFP (control) or LIN28B. B. 
Quantification of invaded cells from (A). Five high power fields were imaged per insert for 
analysis. Results represent means ± SEM. 
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Decreased LIN28B expression reduces trophoblast proliferation 
 To determine whether the reduced LIN28B expression observed in the placentas 
of PE complicated pregnancies also affects trophoblast proliferation, LIN28B was 
knocked down in JEG3 cells or overexpressed in HTR8/SVneo cells (Figure 14A and B). 
These cell lines were chosen because the human trophoblast-like cell line JEG3 cells has 
high basal LIN28B expression, while HTR8/SVneo cells, a human first trimester 
trophoblast cell line, has undetectable levels of LIN28B expression. As shown in Figure 
15, transient knockdown of LIN28B in JEG3 resulted in a ~35% decrease in cell 
proliferation, whereas overexpression of LIN28B in HTR8/SVneo cells resulted in a ~40% 
increase in cell proliferation. Taken together, these data indicate that LIN28B expression 
not only regulates trophoblast migration and invasion, but also proliferation.  
 
LIN28B expression regulates trophoblast differentiation 
 Considering the well-established role of LIN28B in the regulation of cell 
differentiation, along with our data indicating LIN28B is highly expressed in invasive 
EVTs, STs and syncytial sprouts (Figure 6 and 11), we next sought to determine whether 
LIN28B regulates the differentiation of trophoblasts in vitro. As shown in Figure 16A, 
transient knockdown of LIN28B in JEG3 cells resulted in a ~29% reduction of the mRNA 
level of the ST differentiation marker SYN-1. Furthermore, this transient knockdown of 
LIN28B in JEG3 cells resulted in a ~50% increase in the mRNA expression of ITGβ4, an 
integrin subunit enriched on non-invasive villous trophoblasts (Figure 16A). We also 
performed qRT-PCR analysis for SYN-1 and ITGβ4 in HTR8/SVneo cells following 
transient overexpression of LIN28B, however there was no detectable significant change 
in the expression of these genes in this cell line (Figure 16B). Taken together, this 
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invasion, migration, proliferation, and differentiation data indicates that LIN28B 
expression regulates trophoblast differentiation towards a syncytial or invasive 
phenotype. 
 
LIN28B expression regulates inflammation 
 Aberrant expression of inflammatory cytokines, in both the mother and placenta, 
is a characteristic of PE. In particular, TNFα has been shown to be increased in both the 
maternal circulation and the placenta of pregnancies complicated by PE (130, 131). 
Therefore, we aimed to determine if the decreased LIN28B expression levels in the 
placenta of PE complicated pregnancies could potentially result in differential expression 
of TNFα. To answer this question, we performed qRT-PCR for TNFα mRNA expression 
following transient knockdown or overexpression of LIN28B in JEG3 and HTR8/SVneo 
cells, respectively. As shown in Figure 17A, transient knockdown of LIN28B in JEG3 cells 
results in a ~50% increase in TNFα mRNA expression. Furthermore, transient 
overexpression of LIN28B in HTR8/SVneo cells results in a ~42% decrease in the mRNA 
expression of TNFα (Figure 17B). Taken together, these experiments provide in vitro 
evidence that LIN28B regulates the expression of TNFα.  
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Figure 14. Transient knockdown of LIN28B in JEG3 cells and transient 
overexpression of LIN28B in HTR8/SVneo cells  
A. Immunoblot (top), densitometric quantification (left) and qRT-PCR analysis (right) for 
LIN28B expression in JEG3 cells 72 hours after transient transfection with scrambled 
shRNA (control) or and shRNA targeting LIN28B. B. Immunoblot (top), densitometric 
quantification (left) and qRT-PCR analysis (right) for LIN28B expression in HTR8/SVneo 
cells 72 hours after transient transfection with GFP (control) or plasmid encoding 
LIN28B. Results represent means ± SEM. *p<0.05 versus scrambled. #p<0.05 versus 
control.  
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Figure 15. LIN28B expression regulates trophoblast proliferation 
A. Cell proliferation analysis of JEG3 cells 72 hours after transient transfection with 
scrambled shRNA or an shRNA targeting LIN28B. B. Cell proliferation analysis of 
HTR8/SVneo cells 72 hours after transient transfection with GFP (control) or plasmid 
encoding LIN28B. Results represent means ± SEM. *indicates p<0.05 versus scrambled. 
#indicates p<0.05 versus control.  
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Figure 16. LIN28B expression regulates trophoblast differentiation 
A. qRT-PCR analysis for SYN-1 and ITGβ4 in JEG3 cells 72 hours after transient 
transfection with a scrambled shRNA or shRNA targeting LIN28B. B. qRT-PCR analysis 
for SYN-1 and ITGβ4 in HTR8/SVneo cells 72 hours after transient transfection with GFP 
(control) or plasmid encoding LIN28B. Results represent means ± SEM. *indicates p<0.05 
for shLIN28B versus scrambled. 
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Figure 17. LIN28B expression regulates TNFα expression 
A. TNFα expression in JEG3 cells 72 hours following transient transfection of scrambled 
shRNA or shRNA targeting LIN28B. B. TNFα expression in HTR8/SVneo cells 72 hours 
following transient transfection with GFP (control) or plasmid encoding LIN28B. Results 
represent means ± SEM. *indicates p<0.05 versus scrambled. #indicates p<0.05 versus 
control. 
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Decreased LIN28B expression reduces the expression of ELABELA 
 ELABELA is a placentally derived circulating peptide hormone and is an 
endogenous ligand for the apelin receptor. It has recently been shown that mice deficient 
in ELABELA exhibit PE-like symptoms, such as elevate blood pressure and proteinuria, 
likely due to impaired placental angiogenesis (212). Considering that LIN28B is an RNA 
binding protein that has been shown to bind and regulate the expression of thousands of 
genes, we aimed to determine if reduced LIN28B expression in PE affected ELABELA 
expression. Interestingly, as shown in Figure 18A, transient knockdown of LIN28B 
resulted in a ~40% reduction in ELABELA mRNA expression. To complement these 
findings, we measured ELABELA mRNA expression in HTR8/SVneo cell following 
transient overexpression of LIN28B, however these cells do not express ELABELA and 
overexpression of LIN28B did not induce its expression (Figure 18B).  
 
LIN28B regulates the placenta and ESC specific chromosome 19 miRNA cluster 
 The C19MC is a large miRNA cluster that is exclusively expressed in the placenta, 
in ESCs, and in some tumors. Furthermore, miRNAs of the C19MC have been reported 
to be decreased in the placenta of PE complicated pregnancies (126). Considering 
LIN28B is an RNA binding protein that plays a role in the regulation of miRNA expression 
and is also almost exclusively expressed in the placenta, ESCs, and some cancers, while 
also decreased in PE (Figure 7 and 8), we aimed to determine if reduced LIN28B 
expression resulted in decreased C19MC expression. To make this determination, we 
performed qRT-PCR analyses for 5 randomly chosen miRNAs encoded throughout the 
length of the C19MC following transient knockdown of LIN28B. As shown in Figure 19, 
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knockdown of LIN28B resulted in a ~30-50% decrease in all five miRNAs, three of which 
(miR-516a, miR-516b, and miR-519d) reached statistical significance.  
 
Hypoxia decreases LIN28B expression in BEWO and JEG3 cells 
 Shallow implantation in PE is associated with inadequate EVT invasion and 
impaired remodeling of the spiral arteries, thus resulting in insufficient placental perfusion 
and progressively hypoxic conditions (97, 213). Thus far, the results presented here 
indicate that trophoblasts are the main cell type expressing LIN28B, and that LIN28B 
plays a major role in trophoblast migration, invasion, proliferation, and differentiation. 
Therefore, we assessed the effect of hypoxia on LIN28B expression in trophoblasts. To 
accomplish this, JEG3 cells were cultured for 72 hours in hypoxia (1% O2), which resulted 
in a >50% reduction in the mRNA and protein expression levels of LIN28B when 
compared to standard culture conditions (21% O2) (Figure 20). To complement this 
experiment, we also subjected BEWO cells, another trophoblast cell line with high basal 
levels of LIN28B (Figure 21A), to 72 hours of hypoxia and found that the LIN28B mRNA 
and protein expression levels were significantly reduced (Figure 21A-C). These results 
indicate that LIN28B expression is regulated by hypoxia, which may have implications in 
PE. 
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Figure 18. Decreased LIN28B expression reduces ELABELA expression 
A. qRT-PCR analysis for ELABELA in JEG3 cells 72 hours after transient transfection 
with scrambled shRNA or shRNA targeting LIN28B. B. qRT-PCR analysis for ELABELA 
in HTR8/SVneo cells 72 hours after transient transfection with GFP (control) or LIN28B. 
ELABELA expression was undetectable in both conditions in HTR8/SVneo cells. Results 
represent means ± SEM. *indicates p<0.05 versus scrambled. 
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Figure 19. Decreased LIN28B results in reduced expression of the C19MC  
qRT-PCR analysis for the indicated miRNA of the C19MC normalized to U18 in JEG3 
cells 72 hours after transient transfection with scrambled shRNA or shRNA targeting 
LIN28B. Results represent means ± SEM. *indicates p<0.05 for shLIN28B versus 
scrambled 
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Figure 20. Hypoxia reduces LIN28B protein and mRNA expression in JEG3 cells 
A-C. Immunoblot analysis for α-tubulin and LIN28B expression (A), normalized 
densitometric quantification of LIN28B protein expression (B), and qRT-PCR analysis for 
LIN28B mRNA expression (C) in JEG3 cells following culture for 72 hours in standard 
culture conditions (21% oxygen) or hypoxia (1% oxygen). Results represent means ± 
SEM. *indicates p<0.05 for 1% oxygen versus 21% oxygen.  
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Figure 21. Hypoxia reduces LIN28B protein and mRNA expression in BEWO cells 
A-C. Immunoblot analysis for α-tubulin and LIN28B expression (A), normalized 
densitometric quantification of LIN28B protein expression (B), and qRT-PCR analysis for 
LIN28B mRNA expression (C) in BEWO cells following culture for 72 hours in standard 
culture conditions (21% oxygen) or hypoxia (1% oxygen). Results represent means ± 
SEM. *indicates p<0.05 for 1% oxygen versus 21% oxygen.  
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Hypoxia decreases LIN28A expression in JEG3 and BEWO cells 
To determine if LIN28A is subject to the same hypoxic regulation as LIN28B, we 
cultured JEG3 cells in standard culture conditions (21% oxygen) or hypoxia (1% oxygen) 
for 72 hours and measure the LIN28A protein and mRNA expression. As shown in Figure 
22, LIN28A protein and mRNA were significantly reduced following culturing in hypoxia. 
Upon performing this same experiment in BEWO cells, we again found that LIN28A 
protein and mRNA is significantly reduced by hypoxia (Figure 23). These results indicate 
that LIN28A is regulated by hypoxia in a manner similar to that of LIN28B.  
 
Hypoxia increases Let-7a and Let-7g expression in JEG3 and BEWO cells 
To test if there was a concomitant increase in Let-7 miRNA expression with the 
reduction in LIN28A and LIN28B, we performed qRT-PCR for Let-7a and Let-7g in JEG3 
and BEWO cells following 72 hours of culture in hypoxia. As shown in Figure 24, we 
found that expression of both Let-7a and Let-7g were increased, although this increase 
did not attain statistical significance.  
 
Hypoxia decreases SYN-1 and ELABELA and increases TNFα in JEG3 and BEWO cells   
 Considering knockdown of LIN28B led to reduced SYN-1 and ELABELA mRNA 
expression levels, while increasing TNFα mRNA expression levels, and culture in hypoxia 
led to significantly reduced LIN28B expression levels, we aimed to test the effect of 
hypoxia on these markers of trophoblast differentiation and inflammation. Similar to 
LIN28B knockdown experiments, culturing of BEWO and JEG3 cells for 72 hours in 
hypoxic conditions resulted in a >60% (p<0.05) reduction the mRNA levels of SYN-1, and 
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>1000% increase (p<0.05) increase in expression of TNFα in both cell lines compared to 
standard culture conditions (Figure 25). Furthermore, culturing JEG3 cells in hypoxic 
conditions reduced the expression of ELABELA to undetectable levels, while exposure of 
BEWO cells to hypoxic condition resulted in a ~30% decrease in ELABELA expression, 
but did not reach statistical significance (Figure 25). However, unlike LIN28B knockdown 
experiments, hypoxic conditions had no effect on the mRNA expression of ITGβ4.  
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Figure 22. Hypoxia reduces LIN28A protein and mRNA expression in JEG3 cells 
A-C. Immunoblot analysis for α-tubulin and LIN28A expression (A), normalized 
densitometric quantification of LIN28A protein expression (B), and qRT-PCR analysis for 
LIN28A mRNA expression (C) in JEG3 cells following culture for 72 hours in standard 
culture conditions (21% oxygen) or hypoxia (1% oxygen). Results represent means ± 
SEM. *indicates p<0.05 for 1% oxygen versus 21% oxygen.  
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Figure 23. Hypoxia reduces LIN28A protein and mRNA expression in BEWO cells 
A-C. Immunoblot analysis for α-tubulin and LIN28A expression (A), normalized 
densitometric quantification of LIN28A protein expression (B), and qRT-PCR analysis for 
LIN28A mRNA expression (C) in BEWO cells following culture for 72 hours in standard 
culture conditions (21% oxygen) or hypoxia (1% oxygen). Results represent means ± 
SEM. *indicates p<0.05 for 1% oxygen versus 21% oxygen. 
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Figure 24. Hypoxia increases Let-7a and Let-7g in JEG3 and BEWO cells 
A and B. qRT-PCR analysis for Let-7a and Let-7g in JEG3 cells (A) and BEWO cells (B) 
after culture for 72 hours in standard culture conditions (21% oxygen) or hypoxia (1% 
oxygen. Results represent means ± SEM. 
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Figure 25. Hypoxia reduces SYN-1 and ELABELA and increases TNFα in 
trophoblasts 
A and B. qRT-PCR analysis of the indicated gene in JEG3 cells (A) and BEWO cells (B) 
after 72 hours of culture in standard culture conditions (21% oxygen) or hypoxic 
conditions (1% oxygen). Results represent means ± SEM. *indicates p<0.05 for 1% 
oxygen versus 21% oxygen standard culture conditions. 
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Discussion 
Many cases of PE appear to arise from insufficient EVT invasion accompanied by 
impaired remodeling of the maternal spiral arteries resulting in insufficient blood flow to 
the developing fetal-placental unit. This impaired EVT invasion results in extended 
periods of pathologically hypoxic conditions for the growing placenta and fetus. Ultimately, 
this local placental hypoxia is a likely contributor to, or marker of, long-term adverse 
effects on maternal health as well as fetal growth restriction caused by placental 
insufficiency (214, 215). The mechanisms responsible for the development of PE and its 
longstanding adverse health effects, for both the mother and child after birth, are complex 
and under active investigation. Results from the current study revealed that the RNA 
binding protein, LIN28B, is expressed at significantly higher levels than LIN28A in the 
human placenta and is significantly down-regulated at both the mRNA and protein levels 
in placental tissues of term pregnancies affected by PE. Furthermore, the let-7g/LIN28B 
ratio is increased in placentas from PE-complicated compared to normotensive 
pregnancies. The current study also demonstrated that increased LIN28B expression is 
associated with increased EVT invasiveness, both in the placenta in situ and in vitro as 
displayed by immunohistochemistry, scratch wound assays, and Matrigel invasion 
assays. Knockdown of LIN28B in JEG3 cells resulted in a significant decrease in SYN-1, 
ELABELA and miRNAs of the C19MC cluster, and an increase in expression of the non-
invasive trophoblast marker ITGβ4, as well as the pro-inflammatory cytokine TNFα. 
Furthermore, exposure to hypoxia resulted in decreased LIN28A and LIN28B expression 
in the trophoblast-like cell lines BEWO and JEG3. Lastly, exposure to hypoxia decreased 
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SYN-1 and ELABELA mRNA expression, while it increased TNFα and Let-7 expression 
in BEWO and JEG3 cells.  
 This is the first study demonstrating that LIN28B is the predominant paralog of 
LIN28 expressed in the human placenta. LIN28B expression is confirmed to be higher 
than LIN28A in isolated primary DCs, CTs, and STs. Moreover, in situ LIN28B protein is 
expressed significantly higher in CTs and STs when compared to DCs. LIN28B and 
LIN28A share 65% sequence identity and have similar structures that include N-terminal 
cold shock domain, C-terminal Zinc-knuckle domain, and putative nucleolar localization 
sequences. Although, LIN28B has 41 more amino acids and contains C-terminal domain 
with a nuclear localization signal, although both can function in the nucleus and cytosol 
(216). While it is known that LIN28A and LIN28B share similar functions, such as 
regulation of let-7 maturation and regulation of thousands of mRNAs, the predominant 
expression of LIN28B in human placental tissue suggests that LIN28B has a unique role 
in human placenta. For instance, stable isotope labeling by amino acids in cell culture 
(SILAC) studies in stable LIN28B knockdown cell lines have shown that loss of LIN28B 
results in changes in protein expression of thousands of genes, many of which regulate 
progression through the cell cycle (217). Therefore, it is likely that, in addition to regulating 
the expression of Let-7, LIN28B plays a major role in regulating the expression of many 
other genes and the cell cycle in placental cells during development.  
This study also shows that LIN28B expression is decreased in human placentas 
from PE affected pregnancies. We suspect that this decrease in LIN28B is being driven, 
at least in part, by placental hypoxia. However, more studies are needed to determine the 
precise upstream factors leading to the reduction in LIN28B observed in this study. Global 
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decreases in LIN28B expression, on both the mRNA and protein level, were observed 
which indicates changes in transcription and/or post-translational changes resulting in 
protein degradation. Accompanying the decrease in LIN28B observed in this study is an 
increase in the Let-7g and Let-7a miRNA/LIN28B protein ratio. This increase is in 
agreement with previous studies that have shown that LIN28B selectively binds to a 
common GGAG motif in the loop region of pri-Let-7 and pre-Let-7 transcripts, resulting in 
either inhibition of DROSHA (pri-Let-7) or DICER1 RNase III (pre-Let-7) processing (154, 
155, 218-220). In humans, the Let-7 miRNA family contains twelve members and the 
suppression of Let-7g, Let-7b, and Let-7f by LIN28B has been well documented, although 
Let-7b and Let-7f were not tested in this study (158, 221). Based on the well-characterized 
and strong inhibition of maturation of Let-7g by LIN28B, it is no surprise that Let-7g levels 
appear increased in placentas in which LIN28B levels are decreased. Furthermore, 
LIN28B has been shown to inhibit the maturation of other miRNAs, such as miR-107, 
miR-143, and miR-200c, although the expression of these miRNAs in the placenta was 
not tested in this study (222, 223). Potential changes in the expression of these miRNAs 
due to decreased LIN28B expression are important to keep in mind when considering 
changes in gene expression associated with PE.  
The disruption in the LIN28B/Let-7 pathway observed in this study may have major 
implications in long-term health of the fetus. For instance, the LIN28B/let-7 switch has 
been shown to be a major contributor in the control of cellular metabolism through the 
regulation of genes in the insulin-PI3K-mTOR pathway (162). Expression of LIN28A and 
LIN28B has been shown to increase the activating phosphorylation of Akt at serine 473, 
thus suggesting activation of the PI3K-mTOR pathway. Furthermore, this activating 
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phosphorylation is abrogated by the overexpression of Let-7, providing further evidence 
that the LIN28/Let-7 switch plays a major role in cellular metabolism. Elegant in vivo 
studies have also implicated the LIN28/Let-7 switch in the involvement of glucose 
metabolism and homeostasis. For instance, embryonic knockout of LIN28B in mice leads 
to stunted postnatal growth and greatly impaired glucose tolerance, whereas mice 
engineered to overexpress LIN28B grow much larger than wild-type littermates, exhibit 
increased sensitivity to insulin, and display higher glucose metabolism (162, 163). 
Furthermore, fetal muscle-specific LIN28B knockout resulted in decreased adult growth, 
and long-term adverse health effects that mimic metabolic disorder, such as insulin 
resistance, and impaired glucose uptake compared to wild-type controls, which suggests 
a crucial role for pre-natal LIN28B expression in both pre-natal and post-natal 
development (180). On the other hand, mice engineered to overexpress let-7 displayed 
similar phenotypes to LIN28B knockout mice. For instance, they were smaller than wild-
type littermates, had impaired glucose tolerance whether fed a normal or high fat diet, 
and displayed insufficient insulin secretion (162, 164). These results, again, lend more 
evidence to suggest that pre-natal LIN28B expression plays a major role in long-term 
health outcomes. In addition to transgenic and knockout mouse studies, human GWAS 
studies have linked LIN28B to multiple long-term outcomes, including adult height, age of 
both puberty and menarche and the development of type 2 diabetes (224-227). Given all 
of this mounting evidence, it is becoming more clear that early LIN28B expression is a 
major factor involved in long-term health and development. Therefore, the reduced 
LIN28B expression in the placentas of PE-complicated pregnancies observed in this 
study may contribute to the explanation of why children born from PE-complicated 
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pregnancies are often born smaller for gestational age compared to children from 
unaffected pregnancies and have a much greater risk of developing long-term detrimental 
health outcomes, such as metabolic and cardiovascular related diseases including 
diabetes and heart disease (23, 228).  
Proper initiation and progression of pregnancy requires sufficient implantation and 
EVT invasion into the decidua followed by extensive remodeling of the maternal spiral 
vasculature. The EVT invasion and remodeling during early pregnancy is strikingly similar 
to that of cancer metastasis, with the two processes sharing several similar molecular 
pathways (181, 229). In agreement with this, LIN28B has been reported to increase 
cancer cell proliferation and invasion, and its expression has been correlated with poor 
prognosis of multiple cancers, such as hepatocellular carcinoma, acute myeloid leukemia, 
brain cancer, breast cancer, and many others (141, 183, 187). The development of PE is 
frequently associated with impaired EVT invasion accompanied by poor remodeling of 
the spiral arteries resulting in decreased blood flow required by the developing fetal-
placental unit and prolonged pathological hypoxia throughout pregnancy. Accordingly, the 
results of this study demonstrate that invasive interstitial EVTs invading the maternal 
decidua in 1st trimester human placental sections express higher levels of LIN28B 
compared to non-invasive proximal EVTs. Furthermore, overexpression of LIN28B 
increases proliferation, migration and invasion of first trimester HTR8/SVneo cells in vitro. 
Conversely, this study is the first to show that knockdown of LIN28B in JEG3 cells 
decreases cellular proliferation and led to an increase in ITGβ4, an integrin subunit that 
is highly expressed on the surface of non-invasive trophoblasts and helps to regulate cell-
cell adhesion and cell adhesion to the extracellular matrix. Taken together, these findings 
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suggest that high expression levels of LIN28B are required for proper trophoblast 
proliferation and invasion into the maternal decidua. It is possible that LIN28B is 
contributing to this invasion through stimulation of EMT, a process which trophoblasts 
undergo during the transition from non-invasive villous CTs to invasive EVTs, and which 
LIN28B has been shown to induce (190, 192). It is also possible that high LIN28B 
expression is contributing to trophoblast invasiveness indirectly through the repression of 
Let-7, which results in increased expression of extracellular matrix remodeling factors 
and/or growth factors. For instance, Hmga1 and Hmga2 are known targets of Let-7, and 
their expression has been shown to upregulate MMPs, resulting in increased capacity for 
extracellular matrix remodeling (230-234). Therefore, the high level of LIN28B expression 
and the resulting low level of Let-7 expression could potentially be an underlying 
mechanism of increased MMP secretion and trophoblast invasion. However, future 
studies are needed to identify the precise molecular pathway with which LIN28B 
contributes to trophoblast migration and invasion into the decidua.  
Although LIN28B is generally known to inhibit the maturation of miRNAs, this study 
has shown that knockdown of LIN28B in JEG3 cells results in reduced the expression of 
several miRNAs of the C19MC cluster. While it is not currently known if LIN28B directly 
binds any of these miRNAs, these surprising results could potentially be explained by 
epigenetic changes. For instance, the CpG-rich region upstream of the C19MC is prone 
to hypermethylation, which results in reduced C19MC expression, while demethylation of 
the region increases C19MC expression (235). Furthermore, using CHIP-seq analysis a 
recent study showed that, in addition to its RNA binding capabilities, LIN28 can bind 
directly to specific consensus sequences in DNA promoter regions (236). Binding of 
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LIN28A to these specific regions leads to the recruitment of the CpG demethylase TET1, 
thus demethylating the regions and activating transcription, while knockdown of LIN28A 
results in global decreases in the expression of many genes due to decreased 
demethylation (236). Therefore, it is possible that the knockdown of LIN28B in JEG3 cells 
shown herein results in increased methylation of CpG-rich regions upstream of C19MC, 
and thus reduced expression. Moreover, further analysis of recently published PAR-CLIP 
data indicates that LIN28B can interact with CpG rich-Alu repeats that are dispersed 
throughout the C19MC cluster (158). In fact, these CpG rich-Alu repeats are some of the 
most abundant genomic elements encoded throughout the C19MC. Importantly, these 
CpG rich-Alu repeats can function as independent promoters for RNA polymerase III, thus 
transcriptionally activating and driving expression of the miRNAs of the C19MC (237-
239). Furthermore, we recently showed that overexpression of LIN28B in HEK293 cells, 
a cell line which does not typically express LIN28B or the C19MC, resulted in expression 
of some of the miRNAs of the C19MC (240). Considered together, our data showing that 
knockdown of LIN28B results in decreased C19MC expression, while overexpression of 
LIN28B leads to increased C19MC expression, strongly implies that C19MC expression 
is, at least in part, dependent on LIN28B expression. Therefore, the decreased LIN28B 
expression in the placentas of PE-complicated pregnancies described herein may 
contribute to the altered expression of C19MC reported in many cases of PE (126). 
However, further studies are needed to elucidate the specific pathways through which 
suppression of LIN28B results in decreased C19MC expression and whether other 
changes in gene expression are due to a reduction in these miRNAs.  
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We report here for the first time that knockdown of LIN28B in JEG3 cells resulted 
in a significant reduction in the mRNA level of SYN-1. However, overexpression of 
LIN28B in HTR8/SVneo cells did not result in increased expression of SYN-1, which 
indicates that LIN28B alone is likely not sufficient to induce its expression. SYN-1 is 
known to induce cellular membrane fusion and is highly expressed in STs of the placenta. 
Furthermore, SYN-1 has been shown to be decreased in the placenta of PE complicated 
pregnancies, contributing to the overall impaired syncytialization (100, 241). In addition 
to the reduced SYN-1 expression observed upon knockdown of LIN28B, we also show 
that LIN28B is very highly expression in the syncytium of term placentas and the syncytial 
sprouts of first trimester placentas, further indicating a potential link between LIN28B, 
SYN-1, and syncytialization. Together, these knockdown and immunohistochemical 
experiments provide the first evidence that decreased LIN28B expression in PE could 
potentially be a contributing factor to the decreased SYN-1 expression and impaired 
syncytialization observed in the placentas of PE complicated pregnancies. However, the 
direct mechanism underlying these gene expression changes as yet to be elucidated. 
SYN-1 mRNA is not a predicted target of the Let-7 family of miRNAs or other miRNAs 
known to be inhibited by LIN28B, such as miR-107, miR-143, and miR-200c. Therefore, 
the changes in SYN-1 expression associated with changes in LIN28B expression are 
likely due to indirect mechanisms that are not yet characterized.  
Several pro-inflammatory cytokines are documented to play a role in endothelial 
dysfunction and endothelial activation, with aberrations in their expression levels reported 
in the development of PE. One pro-inflammatory cytokine, TNFα, has been reported to 
be elevated in both the amniotic fluid and the maternal plasma of pregnancies affected 
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by PE. Considering LIN28B has been shown to interact with thousands of mRNA 
transcripts to promote or repress their translation, we tested whether LIN28B expression 
levels affect TNFα expression and found that knockdown of LIN28B results in elevated 
levels of TNFα mRNA. Conversely, we show that overexpression of LIN28B in 
HTR8/SVneo cells results in significantly reduced TNFα mRNA expression. This study 
provides the first evidence that LIN28B expression regulates TNFα expression and 
identifies a potential link between decreased LIN28B expression in the placenta and the 
pro-inflammatory conditions presented in PE. Analysis of previously published RNA pull 
down data indicates that LIN28B does not directly interact with TNFα mRNA, thus the 
mechanism behind the increase in TNFα upon knockdown of LIN28B is likely indirectly 
due to decreased LIN28B expression (158). For instance, human TargetScan analysis 
reveals that the C19MC miRNAs miR-516b, miR-519, and miR-525 are predicted to target 
the 3’UTR of TNFα. Therefore, the increased TNFα expression observed upon 
knockdown of LIN28B could potentially be due to decreased repression by the C19MC, 
considering C19MC miRNA expression is reduced when LIN28B is knocked down.  
However, future studies are warranted to determine the specific link between LIN28B and 
the complex inflammatory signaling in PE in general and in regulating TNFα in particular. 
 ELABELA is a peptide hormone that is highly expressed in the developing embryo, 
placenta, serum, and some adult tissues. As an endogenous ligand for the apelin 
receptor, ELABELA has been shown to regulate vascular tone, angiogenesis, and 
vascular development (242). In addition to its proangiogenic functions, it has been 
demonstrated that treatment of trophoblasts with ELABELA results in increased 
trophoblast invasiveness in vitro (212). Furthermore, mice deficient in ELABELA, but not 
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the apelin receptor, display symptoms of PE such as proteinuria and elevated blood 
pressure, with exogenous delivery of ELABELA reversing the PE-like symptoms (75). In 
this study, we show for the first time that knockdown of LIN28B in JEG3 cells results in 
decreased expression of ELABELA. However, we also show that HTR8/SVneo cells do 
not express ELABELA, and its expression is not induced following overexpression of 
LIN28B. This lack of expression in HTR8/SVneo cells could be due to a lack of necessary 
transcription factor expression or hypermethylation of the ELABELA promoter region. It 
has been previously shown that LIN28B can bind thousands of mRNA transcripts, leading 
to increased translation and increased gene expression. However, a previous study using 
an RNA pull down assay has shown that LIN28 does not bind to ELABELA mRNA, 
therefore the changes in ELABELA expression in JEG3 cells due to knockdown of LIN28B 
observed herein must be through an indirect mechanism, rather than direct interaction of 
LIN28B and ELABELA (243). ELABELA is not a predicted target of the Let-7 family of 
miRNAs or other miRNAs known to be inhibited by LIN28B, therefore future studies are 
needed to identify the underlying mechanism responsible for decreased ELABELA 
expression following LIN28B knockdown.   
ITG4 is an integrin subunit that is enriched on the surface of non-invasive, villous 
trophoblasts and decreased on the surface of extravillous invasive trophoblasts. In this 
study we show that knockdown of LIN28B in JEG3 cells results in an increase in the 
expression of ITG4, indicating that decreased LIN28B expression results in a less 
invasive trophoblast phenotype. However, overexpression of LIN28B in HTR8/SVneo 
cells resulted in only a moderate decrease in ITG4 expression, suggesting that LIN28B 
expression alone is not enough to alter the integrin expression pattern in this cell type. 
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While the exact mechanism underlying the increased ITG4 expression upon knockdown 
of LIN28B in JEG3 cells has not been elucidated, it could be potentially explained by post-
transcriptional miRNA regulation. For instance, human TargetScan analysis reveals that 
the C19MC miRNAs miR-524 and miR-519 are predicted to target the 3’UTR of ITGβ4. 
Therefore, it is plausible that the reduced C19MC expression following knockdown of 
LIN28B shown herein could result in increased ITGβ4 expression due to decreased 
repression of the mRNA transcript. However, further studies are necessary to tease out 
the specific mechanisms underlying these changes.  
  It is established that insufficient placental perfusion results in increasingly 
pathological utero-placental hypoxia. The experiments shown herein are the first to report 
that exposure of BEWO or JEG3 cells to hypoxia results in a decrease in the expression 
of LIN28A and LIN28B mRNA and protein, with an accompanying increase in Let-7 
miRNA expression. It has recently been shown that LIN28A can be post-translationally 
modified by MAPK/ERK, with this phosphorylation resulting in increased protein stability 
(244). Furthermore, it has also been demonstrated that MAPK/ERK is downregulated by 
hypoxia in ESCs, while hypoxia has been shown to induce the expression of Let-7 in 
endothelial and cancer cell lines (245-247). Thus, this decrease in stabilizing 
phosphorylation, or the increase in Let-7 expression, could conceivably lead to the 
decreased LIN28A and LIN28B expression following hypoxia reported in this study. This 
study is the first of its kind to show that LIN28B is reduced by hypoxia, which has major 
implications for stem cells, embryogenesis, and/or development, all of which can be 
impacted by hypoxia. The exact mechanism underlying this reduction, as well as its long-
term implications warrants further investigation.  
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In addition to the decrease in LIN28A and LIN28B and the increase in Let-7, 
exposure of JEG3 and BEWO cells to hypoxia lead to reduced mRNA expression of SYN-
1 and ELABELA. Based on human TargetScan analysis neither SYN-1 nor ELABELA are 
predicted to be targets of Let-7, thus their reduced expression is likely due to another 
mechanism (248). Considering SYN-1 and ELABELA are also both significantly reduced 
upon knockdown of LIN28B, it is plausible that LIN28B directly or indirectly regulates the 
expression of these genes, as it is an RNA binding protein that can target many different 
mRNA transcripts. Collectively, the LIN28B- and hypoxia-dependent reduction in SYN-1 
and ELABELA expression likely directly relates to placental insufficiency due to impaired 
angiogenesis and a reduction in syncytiotrophoblast formation, which play an integral role 
in maternal-placental gas and nutrient transport (249, 250). However, future studies 
aiming to elucidate the specific mechanism behind these reductions are warranted. 
 It is plausible that very early on in pregnancy, well before the manifestation of 
measurable clinical symptoms, a currently unknown factor causes LIN28B expression to 
be reduced in placentas of PE affected pregnancies. Based on the well-established roles 
of LIN28B regarding pluripotency, EMT, and cellular proliferation and invasion, in addition 
to the data and observations shown in this study, decreased LIN28B expression during 
blastocyst development, specifically trophectoderm development, could conceivably 
result in impaired implantation and insufficient trophoblast invasion and remodeling of the 
maternal spiral vasculature. Thus, this impaired spiral artery remodeling would result in 
prolonged pathological hypoxia thereby further decreasing LIN28B expression. This 
detrimental feed-forward loop could be an underlying factor in the development of PE 
(Figure 26). However, it is also possible that placental hypoxia triggered by an unknown 
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mechanism leads to the downregulation of LIN28B in PE. Future studies are required to 
elucidate the specific mechanism behind the reduction in LIN28B expression observed 
herein.  
 As explained by the development origin of health and disease (DOHaD) 
hypothesis, environmental factors such as poor nutrition of the mother or fetus, among 
many others, interfere with normal fetal development and likely contribute to long-term 
adverse health outcomes, such as detrimental changes in the metabolism of the child 
(251). However, the exact signal transduction pathways and cellular mechanisms 
underlying this phenomenon are not currently known. Considering fetal LIN28B 
expression is highly correlated with development and long-term changes in growth and 
metabolism, it is pertinent to investigate whether the decreased LIN28B expression in 
placentas from PE-complicated pregnancies contributes to the adverse adulthood health 
outcomes (162, 163, 180). Therefore, we propose the hypothesis that reduced LIN28B 
expression may be a contributing underlying factor in the DOHaD since it is known that: 
1) LIN28B plays a major role in the regulation of long-term cellular growth and 
metabolism; 2) fetal knockout of LIN28B results in long-term adverse health conditions 
such as reduced growth and impaired glucose metabolism; and 3) LIN28B is reduced in 
PE, which is associated with long-term adverse changes in metabolism. Therefore, it is 
plausible that decreased LIN28B expression during development is an underlying factor 
in these changes. Future studies directed at testing this hypothesis may confirm that 
LIN28B contributes to the central mechanism of the DOHaD and may lay the foundation 
for future epidemiological and molecular studies.   
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Figure 26. Schematic model of the contribution of LIN28B to the normal 
physiology of pregnancy and the pathological conditions of PE 
 
A. Simplified model of normal pregnancy in which there exists high levels of LIN28B, 
leading to sufficient trophoblast invasion, adequate spiral artery remodeling, and proper 
placental perfusion. B. Simplified schematic model showing the contribution of decreased 
LIN28B to the development of PE and PE-associated metabolic disorders. 
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Chapter 5 
 
Limitations and Overall Conclusions 
Limitations 
 One limitation to the studies performed herein is the use of the trophoblast-like 
choriocarcinoma cells (JEG3 and BEWO) and immortalized cells derived from first 
trimester villous explants (HTR8/SVneo). Although the use of these cells, which are 
generally accepted for use as in vitro trophoblast models, make performing gene 
manipulation studies easier, the use of primary derived human trophoblasts would add 
more translational relevance. Unfortunately, due to culturing constraints of primary 
isolated human trophoblasts, the experiments performed would not be feasible. Upon 
isolation and culture from a freshly delivered placenta, primary trophoblasts begin to 
spontaneously differentiate into STs after only 2 to 3 days. For the experiments performed 
in this study, cells transfected with an shRNA targeting LIN28B or a plasmid encoding 
LIN28B were allowed to grow for 3 days following transfection to permit sufficient 
knockdown of the endogenously expressed protein or exogenous protein overexpression. 
For these experiments to be performed in primary isolated human trophoblasts, the cells 
would have to be isolated, seeded at the proper density, then transfected and allowed to 
grow for 3 days to permit gene knockdown/overexpression. The numerous gene and 
phenotypic changes that occur during the spontaneous differentiation into 
syncytiotrophoblasts could confound the outcome of the experiments. Therefore, we 
chose to use the cells lines depicted herein for these experiments. In addition to the use 
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of choriocarcinoma derived trophoblast-like cells, another potential cell culture limitation 
in this study is the use of 21% oxygen (i.e. normal culture conditions) for comparison to 
the culture in hypoxia (1% oxygen). Physiologically, 21% oxygen would be considered 
hyperoxia, considering all tissues in the body are exposed to blood-oxygen 
concentrations significantly lower than this. Comparison of LIN28B expression levels in 
trophoblasts cultured in hypoxia (1% oxygen), as well as other more physiologically 
accurate oxygen concentrations, such as 3%, 6%, and 10%, would add additional value 
to these studies.  
Another potential limitation to this study is differences in the clinical data of the 
normal and PE affected cohorts. For instance, there was a marked difference in the 
indication for cesarean section (CS) between the two cohorts. Specifically, 13 individuals 
in the PE cohort underwent CS, 4 of which were due to failure to progress, while 16 
individuals in the normal cohort underwent CS, with the majority being repeat CS and 
none due to failure to progress. It is plausible that this discrepancy could influence the 
findings of this study. However, we identified a widespread decrease in the expression of 
LIN28B, on both the mRNA and protein level. These observed changes are suggestive 
of changes in the stability and degradation of LIN28B protein, as well as changes in 
transcription. Therefore, these differences in LIN28B expression are not likely due to the 
relatively short time between induction of labor and performance of a CS due to the failure 
to progress. However, further studies using more samples from normal and PE affected 
pregnancies that undergo CS due to failure to progress could be conducted to address 
whether the failure to progress and performance of a CS affect the post-delivery placental 
expression of LIN28B. 
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A third potential limitation to the study is the fact that we measured LIN28B 
expression in term placentas of normal and PE affected pregnancies. Therefore, we 
cannot conclusively say that decreased LIN28B causes PE; we can only speculate that 
decreased LIN28B is associated with and contributes to the pathophysiology of PE. It 
would be more informative to measure the expression level of LIN28B early on in 
pregnancy, when the underlying pathophysiological changes associated with PE are 
taking place, to determine if reduced LIN28B expression results in decreased spiral artery 
remodeling and ultimately development of PE. Unfortunately, these experiments are not 
feasible due to only having access to early pregnancy placentas that are from 
pregnancies that have been terminated. We currently have no way of knowing whether 
PE would have been developed during the pregnancy. This limitation could potentially be 
avoided by the use of animal models of PE. However, current rodent models of PE fail to 
fully recapitulate the human condition, and the placental implantation and development 
process in rodents is quite different than that of humans.  
 
Overall conclusions 
 To our knowledge, this study is the first of its kind to examine the expression and 
function of the RNA binding proteins LIN28A and LIN28B in the context of the human 
placenta and pregnancy. Despite the large amount of literature characterizing the function 
of LIN28A and LIN28B, prior to these studies it was not known which paralog, if either, 
was preferentially expressed in the human placenta. Furthermore, the well characterized 
role of LIN28A and LIN28B in regulating cellular proliferation, growth, metabolism, 
differentiation, invasion, and migration suggests that LIN28A or LIN28B may play a role 
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in the invasion of EVTs into the maternal decidua. Therefore, we hypothesized that 
decreased placental LIN28A and/or LIN28B expression impairs trophoblast differentiation 
and invasion, which could contribute to the development of PE.   
 In order to address the role and function of LIN28A or LIN28B in the human 
placenta, we first determined if either paralog is preferentially expressed. Using whole 
placental tissue lysates from normal pregnancies, we found that LIN28B is expressed 
over 1000-fold higher than LIN28A. Furthermore, we found that LIN28B is expressed 
significantly higher than LIN28A in primary isolated human DCs, STs, and CTs, with the 
expression being primarily in placental STs and CTs, rather than maternal DCs. 
Moreover, in situ protein localization further confirmed that LIN28B expression is primarily 
in the STs and CTs, as opposed to the DCs. Moving forward, we next tested whether 
LIN28B is decreased in the placentas of PE complicated pregnancies and found that it is 
significantly reduced on both the mRNA and protein levels, and there is no compensatory 
increase in LIN28A expression. To test if this decreased LIN28B expression may be an 
underlying contributing factor to the development of PE, we examined the LIN28B 
expression in first trimester placentas, when EVT invasion into the maternal decidua is 
prevalent. Using differential immunohistochemical staining, we found that LIN28B is 
highly expressed in syncytial sprouts and its expression increases from proximal, non-
invasive, to distal invasive EVTs, with LIN28B expression being the highest in EVTs 
invading the maternal decidua and very little LIN28B expression in the decidual cells. 
These findings confirm that LIN28B is reduced in PE, and that it plays a role in early EVT 
invasion into the maternal decidua. To support these findings with functional in vitro tests, 
we overexpressed LIN28B and found that this led to increased cell migration, invasion, 
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and proliferation. Furthermore, knockdown of LIN28B expression resulted in decreased 
cellular proliferation.  
 Since LIN28B is an RNA binding protein that is known to target thousands of 
genes, we next aimed to test whether LIN28B expression regulates inflammation or 
trophoblast differentiation, as well as other markers associated with PE. Upon knockdown 
of LIN28B in JEG3 cells, we observed a decrease in the syncytial marker SYN-1, 
accompanied by an increase in the villous trophoblast maker ITGβ4, suggesting that 
LIN28B plays a role in the differentiation of trophoblasts to an invasive and/or syncytial 
phenotype. In addition, knockdown of LIN28B resulted in an increase in the 
proinflammatory cytokine TNFα, which is also increased in PE, while overexpression of 
LIN28B reduced TNFα expression. Moreover, LIN28B knockdown led to reduced 
expression of miRNAs of the C19MC, as well as reduced expression of ELABELA, a 
circulating peptide hormone associated with PE. Collectively, these findings provide 
evidence for the involvement of LIN28B in the differentiation of human trophoblasts.  
 Since the development of PE is associated impaired EVT invasion and exposure 
of the placenta and fetus to prolonged pathological conditions, we tested the effect of 
hypoxia on LIN28B. These experiments showed that LIN28B is drastically reduced upon 
exposure to hypoxia, and this reduction in LIN28B is associated with decreased SYN-1 
expression and increased TNFα expression; results that mirror the effect of shRNA 
mediated LIN28B knockdown. In total, these results show that LIN28B is reduced upon 
exposure to hypoxia, and this reduction is associated with increased inflammation and 
changes in trophoblast differentiation, which may be important in the pathology of PE. 
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 PE is associated with many short- and long-term adverse health outcomes for both 
the mother and child. For instance, children born from PE complicated pregnancies are 
often born early and/or born small for gestational age. Furthermore, adults who were 
exposed to PE in utero have a significantly elevated risk of developing cardiovascular 
disorders, such as hypertension, and metabolic disorders, such as diabetes, when 
compared to adults who were born from normotensive pregnancies. However, the 
underlying mechanism to these long-term adverse health outcomes is not currently 
known. Recently, LIN28B has been shown to play a major role in the regulation of cellular 
growth and metabolism. For instance, fetal knockout of LIN28B in mice results in mice 
that are born smaller than wild type littermates. Furthermore, these mice are prone to 
obesity, and develop glucose intolerance and insulin resistance. Moreover, mice 
engineered to overexpress LIN28B have increased lean weight, improved glucose 
tolerance and insulin sensitivity, and are resistant to the development of obesity when fed 
a high fat diet. Collectively, these elegant mouse studies indicate that fetal LIN28B 
expression plays a major role in long-term health and well-being. Considering loss of fetal 
LIN28B expression results in long-term impaired glucose metabolism and that PE is often 
associated with long-term adverse health outcomes, coupled with our data that shows 
LIN28B is reduced in PE, we propose the hypothesis that decreased LIN28B expression 
in PE may be an underlying contributing factor for the development of the adverse health 
outcomes associated with PE. Future studies aimed at testing this hypothesis may 
confirm LIN28B as an underlying factor in the developmental origins of health and 
diseases.  
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